
==== Front
Cell Biosci
Cell Biosci
Cell & Bioscience
2045-3701
BioMed Central London

39285476
1301
10.1186/s13578-024-01301-w
Review
The roles of OGT and its mechanisms in cancer
Liu Xin
Wang Jing
Xiang Yaoxian
Wang Kangjie
Yan Dong
http://orcid.org/0000-0001-8542-5216
Tong Yingying tongyingying-89@163.com

https://ror.org/01zyn4z03 grid.478016.c 0000 0004 7664 6350 Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149 China
16 9 2024
16 9 2024
2024
14 12118 4 2024
30 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
O-linked-N-acetylglucosaminylation (O-GlcNAcylation) is a common and important post-translational modification (PTM) linking O-linked β-N-acetylglucosamine (O-GlcNAc) to serine and threonine residues in proteins. Extensive research indicates its impact on target protein stability, activity, and interactions. O-linked N-acetylglucosamine transferase (OGT) is a critical enzyme that catalyzes O-GlcNAc modification, responsible for adding O-GlcNAc to proteins. OGT and O-GlcNAcylation are overexpressed in many tumors and closely associated with tumor growth, invasion, metabolism, drug resistance, and immune evasion. This review delineates the biochemical functions of OGT and summarizes its effects and mechanisms in tumors. Targeting OGT presents a promising novel approach for treating human malignancies.

Keywords

OGT
O-GlcNACylation
Cancer-promoting factor
Drug resistance
Immune evasion
http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China 82203576 Tong Yingying capital health research and development of special2022-2-7083 Yan Dong Beijing Municipal Natural Science Foundation7222100 Yan Dong issue-copyright-statement© Society of Chinese Bioscientists in America (SCBA) 2024
==== Body
pmcIntroduction

O-linked-N-acetylglucosaminylation (O-GlcNAcylation), an important protein glycosylation modification, has its origins in the earliest report by Hart’s team [1, 2]. Subsequently, researchers defined O-GlcNAcylation as the process of adding O-linked β-N-acetylglucosamine (O-GlcNAc) to serine or threonine residues in proteins [3]. This modification is implicated in various cellular processes, such as signal transduction, cell cycle regulation, transcriptional control, and metabolism [4–7].

Roughly 2–5% of glucose feeds into the hexosamine biosynthetic pathway (HBP) to generate UDP-GlcNAc, the sugar donor for O-GlcNAcylation [8]. The key rate-limiting enzyme in the HBP pathway is glutamine–fructose-6-phosphate amido transferase (GFAT), which converts fructose-6-phosphate into glucosamine-6-phosphate [9]. O-GlcNAcylation undergoes dynamic and reversible regulation through O-GlcNAc addition and removal. O-GlcNAc transferase (OGT) attaches O-GlcNAc to Ser/Thr residues of substrate proteins, while O-GlcNAcase (OGA) is responsible for its cleavage [10].

The gene responsible for encoding OGT resides on the X chromosome [11]. The OGT protein consists of an N-terminal tetratricopeptide-repeats (TPRs) domain, which binds substrate proteins, and a C-terminal catalytic domain that catalyzes substrate O-GlcNAcylation [12, 13]. Moreover, OGT participates in diverse physiological processes, including fostering nervous system development, regulating mammalian cell physiology, and preserving hematopoietic stem cells. Its expression is elevated in various tumors, suggesting a role in tumor promotion. This review outlines the biochemical functions of OGT and summarizes its role and specific mechanisms in tumors, aiming to provide new insights and approaches for treating malignant tumors.

Structure and basic function of OGT

OGT, a member of the GT-B glycosyltransferase family, is responsible for attaching O-GlcNAc to substrate proteins [14, 15]. OGT is highly conserved across various organisms, from Caenorhabditis elegans to mammals [16]. In humans, alternative splicing produces three OGT isoforms: nucleocytoplasmic OGT (ncOGT), mitochondrial OGT (mOGT), and short OGT (sOGT), each differing in location and length [17]. These isoforms are encoded by the same gene on the X chromosome and feature N-terminal TPRs and a multi-domain catalytic C-terminal [18]. The primary structural difference between the three OGT isoforms is the number of N-terminal TPRs. The longest isoform, ncOGT, contains 13.5 TPRs, while mOGT and sOGT contain 9.5 and 2.5 TPRs, respectively [19, 20]. TPR sequences are primarily involved in the recognition and binding of substrate proteins by OGT [21, 22]. These sequences fold into an antiparallel α-helical structure, with adjacent repeats forming a superhelical structure that binds specific substrates [23, 24]. The enzymatic domain of OGT is located at the C-terminus and catalyzes the O-GlcNAcylation of substrate proteins [12]. This modification affects protein stability, conformation, localization, and activity [25–29]. To date, thousands of proteins have been identified as O-GlcNAcylation targets, including transcription factors, membrane proteins, and cytoskeletal proteins. These modifications regulate gene transcription, cellular responses, protein translation, protein degradation, and other critical biological processes. O-GlcNAcylation impacts cell signal transduction and plays a crucial regulatory role in normal growth and development, as well as in the pathogenesis of various diseases [30–33].

OGT in cancer progression

Roles of OGT in cancer proliferation

Abnormal proliferation is a hallmark of cancer. The carcinogenic effect of OGT is closely associated with its role in driving cell growth in various malignancies, such as liver cancer, gastric cancer (GC), and colorectal cancer (CRC). [34–36]. OGT promotes tumor proliferation primarily through its involvement in regulating protein post-translational modifications (PTMs).

In non-small cell lung cancer cells, OGT overexpression following glutamine deprivation abolishes fructose-1,6-bisphosphatase 1 (FBP1) phosphorylation and enhances β-oxidation gene transcription via FBP1 O-GlcNAcylation, thus promoting cell proliferation [37]. Similar findings have been observed in hepatocellular carcinoma (HCC), highlighting OGT’s crucial role in tumor growth by regulating FBP1 [38]. Additionally, Y box binding protein 1 (YB-1), a well-known oncoprotein, is associated with tumor immune evasion and drug resistance [39, 40]. Liu et al. demonstrated that OGT increases O-GlcNAcylation of YB-1 at Thr126, thereby promoting cell proliferation in HCC [41]. Targeting OGT significantly impedes the progression of high-fructose-induced HCC, with the O-GlcNAcylation of eukaryotic elongation factor 1A1 (EEF1A1) playing a pivotal role in this process [42]. Mitogen-activated protein kinase kinase 2 (MEK2), an important molecule in the MAPK signaling pathway, is related to cell proliferation, differentiation, and stress response [43]. OGT promotes the stability of MEK2 through O-GlcNAcylation at Thr13, thereby enhancing the proliferation and migration of breast cancer cells [44]. Furthermore, microRNA-485-5p modulates CRC proliferation by regulating the stability of B-cell-specific Moloney murine leukemia virus integration region 1 (Bmi-1) via OGT [45]. In xenograft models, mutating the O-GlcNAcylation site of YTH domain family 1 (YTHDF1) reduced tumor growth [46]. DNA polymerase iota (Pol ι) activates glucose-6-phosphate dehydrogenase (G6PD) through Erk-OGT-induced O-GlcNAcylation, promoting the proliferation of esophageal squamous cell carcinoma [47]. Yu et al. found that miR-483 targets OGT to inhibit the proliferation of GC cells [48]. Moreover, the X-inactive-specific transcript (XIST)/miR-424-5p/OGT axis regulates RAF1 glycosylation, impacting liver cancer growth [49]. Long non-coding RNA RHPN1-AS1 is significantly upregulated in CRC cell lines, facilitating CRC progression by modulating the miR-7-5p/OGT axis [50]. These findings indicate that OGT is a key regulator of tumor proliferation (Fig. 1).

Fig. 1 OGT and proliferation regulation in cancer

Roles of OGT in cancer invasion and metastasis

Metastasis, the spread and growth of tumor cells from their original site to new locations in the body, is the leading cause of cancer-related deaths [51]. Despite extensive research on invasion and metastasis mechanisms, this regulatory process remains poorly understood. Recent studies have identified OGT as a key regulator of tumor invasion and metastasis.

Epithelial-mesenchymal transition (EMT) is the phenotypic change of cells from an epithelial to a mesenchymal state, resulting in increased motility and invasiveness of tumor cells [52]. EMT is characterized by the loss of epithelial cell-cell connections, cytoskeletal reorganization, decreased expression of E-cadherin, and increased N-cadherin [53]. Numerous studies have explored EMT’s role in promoting tumor cell invasion and malignancy. Jiang et al. found that knocking down enhancer of zeste homolog 2 (EZH2) in colorectal cancer partially reverses the EMT changes induced by OGT-mediated O-GlcNAcylation [54]. Additionally, OGT knockdown has been shown to inhibit the expression of EMT markers (N-cadherin and Slug), migration, and invasion in lung cancer cells, with the interaction between OGT and STAT3 playing a crucial role in this process [55]. Moreover, OGT knockdown in HO-8910PM cells resulted in decreased O-GlcNAcylation and increased expression of E-cadherin [56].

Matrix metalloproteinases (MMPs), members of the metzincin protease superfamily, degrade the extracellular matrix (ECM) [57]. MMPs participate in physiological processes such as embryonic development and wound healing and play a vital role in enhancing tumor cell migration and invasion [58, 59]. OGT regulates matrix metalloproteinase levels, thereby affecting tumor metastasis. Qiao et al. found that suppressing OGT weakened the migration ability of esophageal cancer cells by significantly reducing the expression of matrix metalloproteinase 9 (MMP9) in Eca-109 cells [60]. Furthermore, OGT knockdown in prostate cancer cell lines was associated with reduced expression of MMP-2, MMP-9, and vascular endothelial growth factor (VEGF), thereby inhibiting invasion and angiogenesis through the regulation of the oncogenic transcription factor forkhead box M1 (FoxM1) [61].

OGT orchestrates O-GlcNAcylation to drive the migration and invasion of papillary thyroid cancer by activating Yes-associated protein (YAP) at the Ser109 modification site [62]. Lv et al. identified upregulated OGT expression in HCC, demonstrating its role in promoting tumor aggressiveness through OGT-mediated O-GlcNAcylation, which stabilizes ras-related protein Rab-10 (RAB10) [63]. CD36, a cell membrane protein, mediates fatty acid uptake and is associated with fatty acid absorption in the heart, skeletal muscle, and adipose tissue [64, 65]. Jiang et al. confirmed that fatty acids promote gastric cancer metastasis by inducing CD36 expression via OGT-mediated O-GlcNAcylation [66]. YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) plays a crucial role in N6-methyladenosine (m6A) modification, regulating mRNA degradation [67, 68]. OGT promotes hepatitis B virus-related HCC migration and invasion by mediating O-GlcNAcylation of YTHDF2 at Ser263 [69]. Wang et al. found that reticulon 2 (RTN2) interacts with OGT and is modified by O-GlcNAc; inhibiting OGT abolishes the stimulatory effects of RTN2 on cell migration [70]. SRC-associated in mitosis of 68 kDa (SAM68) is O-GlcNAcylated and predominantly interacts with OGT in the nucleus, promoting lung cancer cell migration and invasion [71]. Multiple studies have linked MORC family CW-type zinc finger 2 (MORC2) with DNA damage and resistance to radiotherapy and chemotherapy in breast cancer [72, 73]. Liu et al. found that OGT O-GlcNAcylates MORC2 at Thr556, thereby promoting breast cancer migration, invasion, and metastasis [74]. Reginato’s team demonstrated that reducing OGT expression significantly decreases FoxM1 protein levels, inhibiting breast cancer cell growth and invasion [75]. Non-coding RNAs also regulate breast cancer progression by altering OGT expression. Inhibition of OGT by miR-24 reduces the stability of forkhead box protein A1 (FOXA1), thereby inhibiting breast cancer cell invasion [76]. Overexpression of OGT significantly enhances O-GlcNAcylation in TAK1 binding protein 3 (TAB3), promoting migration and invasion of triple-negative breast cancer (TNBC) cells in vivo and in vitro [77]. Dysregulation of the NF-κB pathway is increasingly recognized as a key regulator of tumor progression and drug resistance [78, 79]. Ali et al. confirmed that OGT knockdown reduced CXCR4 expression by decreasing O-GlcNAcylation of NF-κB p65 (p65), inhibiting cervical cancer metastasis [80]. Niu et al. showed that OGT-mediated O-GlcNAcylation regulates ras homolog family member A (RhoA) activity in ovarian cancer cells, affecting their migration and invasion [81]. These studies indicate that OGT overexpression significantly promotes tumor cell invasion into other tissues, facilitating their survival and cancer spread. Therefore, targeting OGT may help inhibit tumor metastasis (Fig. 2) [82–86].

Fig. 2 OGT in cancer invasion and metastasis regulation

Roles of OGT in cancer metabolism

Abnormal cancer metabolism plays a crucial role in tumorigenesis, metastasis, and drug resistance [87]. Glucose, lipid, and amino acid metabolism in tumor tissue undergo significant changes compared to normal tissue [88]. Studies have shown that OGT is directly or indirectly involved in the regulation of tumor metabolic processes.

Most tumor cells produce adenosine triphosphate (ATP) primarily through glycolysis, even under adequate oxygen levels. This phenomenon, known as the Warburg effect, supports tumor cell growth [89]. Phosphoglycerate kinase 1 (PGK1) is the first ATP-generating enzyme in glycolysis, and its expression is linked to tumor progression [90–92]. Research has shown that OGT overexpression enhances PGK1 activity by increasing its O-GlcNAcylation. Blocking T255 O-GlcNAcylation of PGK1 inhibits glycolysis, enhances the mitochondrial tricarboxylic acid (TCA) cycle, and suppresses colon cancer growth [93]. Additionally, transient expression of wild-type OGT increases PKM2 O-GlcNAcylation, suppresses pyruvate kinase activity in HeLa cells, stimulates aerobic glycolysis, and promotes tumor growth [94]. OGT-mediated O-GlcNAcylation also enhances the stability of isocitrate dehydrogenase 2 (IDH2) protein, thereby activating the NF-κB signaling pathway, reprogramming glucose metabolism, and promoting CRC progression [95].

Reprogramming lipid metabolism is a hallmark of many malignancies. Increased fat uptake and lipogenesis occur in various cancers, leading to rapid tumor growth. Lipids form the basic structure of membranes and also serve as signaling molecules and energy sources [96, 97]. Sterol regulatory element-binding protein 1 (SREBP-1) is a major transcription factor controlling lipid metabolism and a key link between oncogenic signaling and tumor metabolism [98]. OGT regulates the expression of SREBP-1 in a proteasomal and AMP-activated protein kinase (AMPK)-dependent manner, thereby altering lipid metabolism and impacting breast cancer cell survival [99].

Acetyl-CoA, produced by acetyl-CoA synthetase 2 (ACSS2) through the catalysis of acetate, is crucial for tumor growth and survival [100, 101]. OGT has been shown to regulate glioblastoma acetate metabolism by influencing cyclin-dependent kinase 5 (CDK5)-dependent ACSS2 phosphorylation. Moreover, drugs targeting OGT and CDK5 have demonstrated efficacy in reducing glioblastoma tumors in vitro [102]. Therefore, OGT plays a significant role in the metabolic reprogramming of tumors and represents a promising therapeutic target (Table 1).

Table 1 Roles of OGT in cancer metabolism

Molecular pathway	Function	References	
OGT/PGK1	Promotes the glycolysis and growth; Inhibit mitochondrial TCA cycle	[93]	
OGT/PKM2	Promotes the aerobic glycolysis and growth	[94]	
OGT/IDH2	Promotes the proliferation and lactic acid production; Reduces ROS production	[95]	
OGT/SREBP-1	Promotes the cell survival and lipid synthesis	[99]	
OGT/CDK5	Regulates acetate metabolism	[102]	

Roles of OGT in drug resistance

Due to the high morbidity and mortality associated with tumors, significant efforts have been made to develop anticancer drugs. These drugs play a crucial role in inhibiting tumor cell metastasis and reducing tumor cell survival. However, tumor cells can alter multiple molecular pathways to develop drug resistance [103, 104].

Platinum-based drugs are commonly used in the treatment of ovarian cancer (OC), but the development of drug resistance remains a significant challenge [105]. Reducing OGT-mediated O-GlcNAcylation of synaptosome-associated protein-23 (SNAP-23) promotes cisplatin resistance by inducing exosome secretion in OC [106]. Additionally, the downregulation of OGT, leading to reduced O-GlcNAcylation of synaptosome-associated protein-29 (SNAP-29), enhances cisplatin-induced autophagy, making OC cells less responsive to cisplatin treatment [107]. Huang et al. demonstrated that OGT interacts with kelch-like ECH-associated protein 1 (KEAP1) and promotes its glycosylation in A2780 and A2780/DDP cell lines. Furthermore, miR-181d enhances OC resistance to cisplatin by regulating the OGT/KEAP1/Nrf2 axis both in vitro and in vivo [108].

5-fluorouracil (5-FU) is a crucial drug for treating colorectal cancer, targeting thymidylate synthase (TS) and its metabolites [109, 110]. Very et al. showed that TS undergoes O-GlcNAcylation through its interaction with OGT, which impedes proteasomal degradation and enhances its stability. Knockdown of OGT reduced cancer cell sensitivity to 5-FU by lowering both TS protein levels and activity [111].

Proteasome inhibitors are used to treat multiple myeloma and mantle cell lymphoma [112]. Inhibition of OGT in NCI-H460 cells and their xenograft model increases cancer cell sensitivity to proteasome inhibitors. This effect is due to the stabilization of nuclear factor erythroid 2-related factor 1 (NRF1) via OGT-catalyzed O-GlcNAcylation, leading to the upregulation of proteasome subunit genes [113].

Osteosarcoma, a common primary bone tumor, shows a reduced survival rate post-metastasis [114]. Methotrexate is an approved therapeutic drug for osteosarcoma [115]. Sun et al. identified that lncRNA EBLN3P increases the resistance of osteosarcoma cells to methotrexate by enhancing the miR-200a-3p/OGT axis [116]. Additionally, docetaxel is a chemotherapy drug approved for prostate cancer treatment [117]. Xia et al. confirmed that miR-140 induces prostate cancer cell sensitivity to docetaxel in an OGT-dependent manner. Knockdown of OGT sensitizes prostate cancer cells to docetaxel [118]. Cisplatin-based systemic chemotherapy is the standard treatment for advanced bladder cancer [119]. Wang et al. observed that reducing OGT expression increased bladder cancer cell sensitivity to cisplatin [120]. Furthermore, gemcitabine and paclitaxel are also used in bladder cancer treatment [121]. OGT knockdown significantly enhanced the sensitivity of drug-resistant bladder cancer cells to these chemotherapy drugs [122].

Based on these studies, OGT-mediated O-GlcNAcylation is associated with tumor treatment resistance. However, current research on targeting OGT for overcoming drug resistance is still limited. This aspect should be further explored in future studies.

Roles of OGT in apoptosis

Apoptosis, first defined as a programmed cell death mode in 1972, is characterized by nuclear and chromatin condensation, as well as the formation of apoptotic bodies, which can be observed through light microscopy [123–125]. This process is crucial for maintaining homeostasis in normal tissues, including the gastrointestinal tract, immune system, and skin [126, 127]. However, abnormal apoptosis occurs during tumor progression, leading to reduced apoptosis in tumor cells and enhanced survival [128]. Given OGT’s role in promoting tumor progression, studies have shown that it inhibits tumor cell apoptosis. For instance, in HCC, OGT highly O-GlcNAcylates speckle-type POZ protein (SPOP) at Ser96, facilitating its nuclear entry and inhibiting apoptosis of liver cancer cells [129]. Yu et al. discovered that OGT-mediated O-GlcNAcylation influences integrin α5 (ITGA5) protein stability, promoting tumor cell growth and tumorigenesis while reducing apoptosis [130]. Additionally, OGT O-GlcNAcylates Bmi-1 at Ser255, thus inhibiting apoptosis in prostate cancer cells [131]. Nuclear and spindle-associated protein 1 (NUSAP1) has been shown to promote bladder cancer progression through the TGF-β signaling pathway, and its expression is also associated with lymph node metastasis and survival prognosis [132, 133]. The protein stability of NUSAP1 decreases after knocking down OGT expression in HT-1376 and T24 cells to reduce O-GlcNAcylation, thus promoting bladder cancer cell apoptosis [134]. Therefore, targeting OGT may be advantageous in inducing tumor cell apoptosis (Fig. 3).

Fig. 3 Roles of OGT in the regulation of apoptosis, cancer stem-like cells properties, ferroptosis and immune escape in cancer

Roles of OGT in cancer stem-like cells properties

Tumor initiation and progression are regulated by cancer stem cells (CSCs), which possess self-renewal, plasticity, and differentiation capabilities that promote metastasis, drug resistance, and recurrence [135, 136]. Eukaryotic initiation factor 4E (eIF4E) and RAF proto-oncogene serine/threonine-protein kinase (RAF1) are key targets of sorafenib [137, 138]. Research has shown that OGT enhances the stem cell-like potential of HCC cells by upregulating eIF4E [139]. Additionally, OGT establishes a feedback loop with Krüppel-like factor 8 (KLF8), modulating CSC phenotypes and increasing paclitaxel resistance [140]. Therefore, identifying the signaling networks that regulate CSC properties via OGT could contribute to more effective tumor treatments (Fig. 3).

Roles of OGT in ferroptosis

Ferroptosis is a recently identified mode of cell death with unique properties and functions, implicated in various diseases, including tumors, renal disease, and cardiovascular disease [141–143]. It is primarily characterized by cytological changes such as the reduction or disappearance of mitochondrial cristae and the condensation of mitochondrial membranes [144, 145]. Recent studies have shown that OGT is associated with ferroptosis in tumors.

Solute carrier family 7, member 11 (SLC7A11), a cystine/glutamate antiporter, promotes cystine import into cells, thereby inhibiting lipid peroxidation and ferroptosis [146, 147]. It has been reported that OGT promotes cystine uptake by HCC cells through O-GlcNAcylation of SLC7A11 at the Ser26 site, leading to ferroptosis inhibition in HCC [148]. Hypoxia-inducible factor 2α (HIF-2α), a hypoxia-related transcription factor, promotes renal cancer progression [149]. OGT was found to increase HIF-2α protein levels in clear cell renal cell carcinoma by inhibiting ubiquitin-proteasome-mediated degradation. Moreover, the OGT/HIF-2α axis modulates the sensitivity of clear cell renal cell carcinoma to ferroptosis [150]. These findings indicate that OGT plays a crucial role in the ferroptosis process, although the regulatory mechanism requires further investigation (Fig. 3).

Roles of OGT in autophagy

Autophagy is a self-degradative process essential for maintaining cellular homeostasis under stress conditions [151, 152]. Well-known regulatory pathways of autophagy include AMPK, PI3K/Akt/mTOR, and Beclin-1 [153]. Recent studies have highlighted the role of OGT in autophagy. Jin et al. demonstrated that overexpression of OGT in bladder cancer cells increases the O-GlcNAcylation level of AMPKα, resulting in altered autophagy flux [154]. Further research is required to elucidate the interaction between OGT and autophagy-related molecules and to characterize its role in tumor progression.

Roles of OGT in immune escape

Since the early 20th century, researchers have explored the role of the immune system in tumor development. Tumor immunosurveillance is a critical process where the immune system monitors, identifies, and eliminates tumor cells [155, 156]. Immune checkpoint proteins, such as Programmed Death-Ligand 1 (PD-L1) and its receptor PD-1, are closely related to tumor immune evasion. PD-L1 interacts with PD-1 on cytotoxic T lymphocytes, transmitting inhibitory signals that weaken the tumor-killing function of these cells [157, 158]. Recent studies have reported that OGT is involved in regulating the expression of immune checkpoint proteins. OGT has been implicated in promoting tumor immune evasion by inhibiting the lysosomal degradation of PD-L1 [159]. Yuan et al. demonstrated that exosomal OGT enhances immune evasion of esophageal cancer stem cells by upregulating PD-1 expression in CD8+ T cells [160]. These findings indicate that OGT plays a role in tumor immune evasion. Further research is needed to determine whether OGT can regulate other immune checkpoint molecules (Fig. 3).

Targeting OGT and O-GlcNAcylation

In most human tumors, OGT functions as an oncoprotein, promoting tumor growth, metastasis, and drug resistance by activating signaling pathways such as proliferation, EMT, and anti-apoptosis. Therefore, targeting OGT is a promising strategy for cancer treatment. For instance, quercetin has been reported to induce cell death in cervical cancer by reducing the expression of OGT, overall O-GlcNAc, and O-GlcNAcylated AMPK [161]. Similarly, corosolic acid inhibits liver cancer progression by decreasing OGT expression and O-GlcNAcylation levels in cancer cells [162]. A number of small molecule compounds targeting OGT activity or OGT-mediated O-GlcNAcylation have been produced, such as OSMI-1 and OSMI-4, and have been widely used in tumor research [163, 164]. OSMI-1 significantly inhibits the proliferation and migration of thyroid cancer cells and slows the occurrence of liver tumors [62, 69].

Moreover, combination therapies have proven more effective than monotherapies in treating tumors. For example, astragalus polysaccharide reduces OGT levels and increases OGA levels in liver cancer cells, thereby downregulating O-GlcNAcylation and promoting doxorubicin-induced apoptosis [165]. A notable increase in cell death has been observed with the coadministration of OSMI-1 and temozolomide. These findings highlight OGT as a promising drug target. However, many phytochemicals and small molecule inhibitors face challenges such as low bioavailability and solubility in human applications. Future applications could overcome these limitations through the use of nanomaterials [166].

Conclusion and perspectives

This review provides an overview of the biological functions of OGT, with a particular focus on its impact on tumors. Elevated levels of OGT expression are commonly observed in tumors. OGT-mediated O-GlcNAcylation promotes tumor cell proliferation and induces EMT, facilitating MMP expression, which is associated with tumor invasion and metastasis. Tumor metabolic reprogramming is also linked to OGT, thereby influencing tumor progression. Furthermore, the OGT/O-GlcNAcylation pathway inhibits apoptosis and ferroptosis, promotes tumor immune escape, and ultimately enhances tumor growth. Notably, OGT mediates drug resistance, making it a critical target for altering tumor cell sensitivity to anticancer treatments. Consequently, small molecule compounds have been developed to inhibit the OGT/O-GlcNAcylation pathway. Knockdown of OGT has been shown to reduce malignant tumor behavior both in vitro and in vivo. Future efforts should focus on translating these research findings into clinical applications to improve cancer patient outcomes.

Acknowledgements

We sincerely thank all the members who contributed to the study.

Author contributions

Writing—original draft preparation, X.L.; writing—review and editing, J.W., Y.X., K.W., Y.T., and D.Y.; visualization, X.L.; supervision, Y.T. and D.Y.; project administration, J.W., Y.X., and K.W.; funding acquisition, Y.T. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by funding from the National Natural Science Foundation of China (No. 82203576), capital health research and development of special (2022-2-7083) and Beijing Municipal Natural Science Foundation (No. 7222100).

Data availability

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflict of interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. -Schjoldager KT Narimatsu Y Joshi HJ Clausen H Global view of human protein glycosylation pathways and functions Nat Rev Mol Cell Biol 2020 21 12 729 49 10.1038/s41580-020-00294-x 33087899
Schjoldager KT, Narimatsu Y, Joshi HJ, Clausen H. Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol. 2020;21(12):729–49. 10.1038/s41580-020-00294-x.33087899
2. -Torres CR Hart GW Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc J Biol Chem 1984 259 5 3308 17 10.1016/S0021-9258(17)43295-9 6421821
Torres CR, Hart GW. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem. 1984;259(5):3308–17.6421821
3. -Holt GD Snow CM Senior A Haltiwanger RS Gerace L Hart GW Nuclear pore complex glycoproteins contain cytoplasmically disposed O-linked N-acetylglucosamine J Cell Biol 1987 104 5 1157 64 10.1083/jcb.104.5.1157 3571327
Holt GD, Snow CM, Senior A, Haltiwanger RS, Gerace L, Hart GW. Nuclear pore complex glycoproteins contain cytoplasmically disposed O-linked N-acetylglucosamine. J Cell Biol. 1987;104(5):1157–64. 10.1083/jcb.104.5.1157.3571327
4. -Wells L Vosseller K Hart GW Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc Sci (New York NY) 2001 291 5512 2376 8 10.1126/science.1058714
Wells L, Vosseller K, Hart GW. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Sci (New York NY). 2001;291(5512):2376–8. 10.1126/science.1058714.
5. -Drougat L Olivier-Van Stichelen S Mortuaire M Foulquier F Lacoste AS Michalski JC Lefebvre T Vercoutter-Edouart AS Characterization of O-GlcNAc cycling and proteomic identification of differentially O-GlcNAcylated proteins during G1/S transition Biochim Biophys Acta 2012 1820 12 1839 48 10.1016/j.bbagen.2012.08.024 22967762
Drougat L, Olivier-Van Stichelen S, Mortuaire M, Foulquier F, Lacoste AS, Michalski JC, Lefebvre T, Vercoutter-Edouart AS. Characterization of O-GlcNAc cycling and proteomic identification of differentially O-GlcNAcylated proteins during G1/S transition. Biochim Biophys Acta. 2012;1820(12):1839–48. 10.1016/j.bbagen.2012.08.024.22967762
6. -Liu AR Ramakrishnan P Regulation of Nuclear factor-kappab function by O-GlcNAcylation in inflammation and Cancer Front cell Dev Biology 2021 9 751761 10.3389/fcell.2021.751761
Liu AR, Ramakrishnan P. Regulation of Nuclear factor-kappab function by O-GlcNAcylation in inflammation and Cancer. Front cell Dev Biology. 2021;9:751761. 10.3389/fcell.2021.751761.
7. -Ferrer CM Lynch TP Sodi VL Falcone JN Schwab LP Peacock DL Vocadlo DJ Seagroves TN Reginato MJ O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway Mol Cell 2014 54 5 820 31 10.1016/j.molcel.2014.04.026 24857547
Ferrer CM, Lynch TP, Sodi VL, Falcone JN, Schwab LP, Peacock DL, Vocadlo DJ, Seagroves TN, Reginato MJ. O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. Mol Cell. 2014;54(5):820–31. 10.1016/j.molcel.2014.04.026.24857547
8. -Marshall S Bacote V Traxinger RR Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance J Biol Chem 1991 266 8 4706 12 10.1016/S0021-9258(19)67706-9 2002019
Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 1991;266(8):4706–12.2002019
9. -Akella NM Ciraku L Reginato MJ Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer BMC Biol 2019 17 1 52 10.1186/s12915-019-0671-3 31272438
Akella NM, Ciraku L, Reginato MJ. Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer. BMC Biol. 2019;17(1):52. 10.1186/s12915-019-0671-3.31272438
10. -Hart GW Housley MP Slawson C Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins Nature 2007 446 7139 1017 22 10.1038/nature05815 17460662
Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 2007;446(7139):1017–22. 10.1038/nature05815.17460662
11. -Nolte D Müller U Human O-GlcNAc transferase (OGT): genomic structure, analysis of splice variants, fine mapping in Xq13.1. Mammalian genome Official J Int Mammalian Genome Soc 2002 13 1 62 4 10.1007/s00335-001-2108-9
Nolte D, Müller U. Human O-GlcNAc transferase (OGT): genomic structure, analysis of splice variants, fine mapping in Xq13.1. Mammalian genome. Official J Int Mammalian Genome Soc. 2002;13(1):62–4. 10.1007/s00335-001-2108-9.
12. -Lazarus MB Nam Y Jiang J Sliz P Walker S Structure of human O-GlcNAc transferase and its complex with a peptide substrate Nature 2011 469 7331 564 7 10.1038/nature09638 21240259
Lazarus MB, Nam Y, Jiang J, Sliz P, Walker S. Structure of human O-GlcNAc transferase and its complex with a peptide substrate. Nature. 2011;469(7331):564–7. 10.1038/nature09638.21240259
13. -Lubas WA Hanover JA Functional expression of O-linked GlcNAc transferase. Domain structure and substrate specificity J Biol Chem 2000 275 15 10983 8 10.1074/jbc.275.15.10983 10753899
Lubas WA, Hanover JA. Functional expression of O-linked GlcNAc transferase. Domain structure and substrate specificity. J Biol Chem. 2000;275(15):10983–8. 10.1074/jbc.275.15.10983.10753899
14. -Lairson LL Henrissat B Davies GJ Withers SG Glycosyltransferases: structures, functions, and mechanisms Annu Rev Biochem 2008 77 521 55 10.1146/annurev.biochem.76.061005.092322 18518825
Lairson LL, Henrissat B, Davies GJ, Withers SG. Glycosyltransferases: structures, functions, and mechanisms. Annu Rev Biochem. 2008;77:521–55. 10.1146/annurev.biochem.76.061005.092322.18518825
15. -Zhang N Jiang H Zhang K Zhu J Wang Z Long Y He Y Feng F Liu W Ye F Qu W OGT as potential novel target: structure, function and inhibitors Chemico-Biol Interact 2022 357 109886 10.1016/j.cbi.2022.109886
Zhang N, Jiang H, Zhang K, Zhu J, Wang Z, Long Y, He Y, Feng F, Liu W, Ye F, Qu W. OGT as potential novel target: structure, function and inhibitors. Chemico-Biol Interact. 2022;357:109886. 10.1016/j.cbi.2022.109886.
16. -Lubas WA Frank DW Krause M Hanover JA O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats J Biol Chem 1997 272 14 9316 24 10.1074/jbc.272.14.9316 9083068
Lubas WA, Frank DW, Krause M, Hanover JA. O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats. J Biol Chem. 1997;272(14):9316–24. 10.1074/jbc.272.14.9316.9083068
17. -Hanover JA Yu S Lubas WB Shin SH Ragano-Caracciola M Kochran J Love DC Mitochondrial and nucleocytoplasmic isoforms of O-linked GlcNAc transferase encoded by a single mammalian gene Arch Biochem Biophys 2003 409 2 287 97 10.1016/s0003-9861(02)00578-7 12504895
Hanover JA, Yu S, Lubas WB, Shin SH, Ragano-Caracciola M, Kochran J, Love DC. Mitochondrial and nucleocytoplasmic isoforms of O-linked GlcNAc transferase encoded by a single mammalian gene. Arch Biochem Biophys. 2003;409(2):287–97. 10.1016/s0003-9861(02)00578-7.12504895
18. -Kreppel LK Blomberg MA Hart GW Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats J Biol Chem 1997 272 14 9308 15 10.1074/jbc.272.14.9308 9083067
Kreppel LK, Blomberg MA, Hart GW. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J Biol Chem. 1997;272(14):9308–15. 10.1074/jbc.272.14.9308.9083067
19. -Love DC Kochan J Cathey RL Shin SH Hanover JA Mitochondrial and nucleocytoplasmic targeting of O-linked GlcNAc transferase J Cell Sci 2003 116 Pt 4 647 54 10.1242/jcs.00246 12538765
Love DC, Kochan J, Cathey RL, Shin SH, Hanover JA. Mitochondrial and nucleocytoplasmic targeting of O-linked GlcNAc transferase. J Cell Sci. 2003;116(Pt 4):647–54. 10.1242/jcs.00246.12538765
20. -Liu L Li L Ma C Shi Y Liu C Xiao Z Zhang Y Tian F Gao Y Zhang J Ying W Wang PG Zhang L O-GlcNAcylation of Thr(12)/Ser(56) in short-form O-GlcNAc transferase (sOGT) regulates its substrate selectivity J Biol Chem 2019 294 45 16620 33 10.1074/jbc.RA119.009085 31527085
Liu L, Li L, Ma C, Shi Y, Liu C, Xiao Z, Zhang Y, Tian F, Gao Y, Zhang J, Ying W, Wang PG, Zhang L. O-GlcNAcylation of Thr(12)/Ser(56) in short-form O-GlcNAc transferase (sOGT) regulates its substrate selectivity. J Biol Chem. 2019;294(45):16620–33. 10.1074/jbc.RA119.009085.31527085
21. -Allan RK Ratajczak T Versatile TPR domains accommodate different modes of target protein recognition and function Cell Stress Chaperones 2011 16 4 353 67 10.1007/s12192-010-0248-0 21153002
Allan RK, Ratajczak T. Versatile TPR domains accommodate different modes of target protein recognition and function. Cell Stress Chaperones. 2011;16(4):353–67. 10.1007/s12192-010-0248-0.21153002
22. -Joiner CM Levine ZG Aonbangkhen C Woo CM Walker S Aspartate residues far from the active site drive O-GlcNAc transferase substrate selection J Am Chem Soc 2019 141 33 12974 8 10.1021/jacs.9b06061 31373491
Joiner CM, Levine ZG, Aonbangkhen C, Woo CM, Walker S. Aspartate residues far from the active site drive O-GlcNAc transferase substrate selection. J Am Chem Soc. 2019;141(33):12974–8. 10.1021/jacs.9b06061.31373491
23. -Jínek M Rehwinkel J Lazarus BD Izaurralde E Hanover JA Conti E The superhelical TPR-repeat domain of O-linked GlcNAc transferase exhibits structural similarities to importin alpha Nat Struct Mol Biol 2004 11 10 1001 7 10.1038/nsmb833 15361863
Jínek M, Rehwinkel J, Lazarus BD, Izaurralde E, Hanover JA, Conti E. The superhelical TPR-repeat domain of O-linked GlcNAc transferase exhibits structural similarities to importin alpha. Nat Struct Mol Biol. 2004;11(10):1001–7. 10.1038/nsmb833.15361863
24. Blatch GL, Lässle M. The tetratricopeptide repeat: a structural motif mediating protein-protein interactions. BioEssays: News Reviews Mol Cell Dev Biology. 1999;21(11):932–9. 10.1002/(SICI)1521-1878(199911)21:11%3C932::AID-BIES5%3E3.0.CO;2-N.
25. -Wang Y Shu H Liu J Jin X Wang L Qu Y Xia M Peng P Feng Y Wei M EGF promotes PKM2 O-GlcNAcylation by stimulating O-GlcNAc transferase phosphorylation at Y976 and their subsequent association J Biol Chem 2022 298 9 102340 10.1016/j.jbc.2022.102340 35931120
Wang Y, Shu H, Liu J, Jin X, Wang L, Qu Y, Xia M, Peng P, Feng Y, Wei M. EGF promotes PKM2 O-GlcNAcylation by stimulating O-GlcNAc transferase phosphorylation at Y976 and their subsequent association. J Biol Chem. 2022;298(9):102340. 10.1016/j.jbc.2022.102340.35931120
26. -Ding X Jiang W Zhou P Liu L Wan X Yuan X Wang X Chen M Chen J Yang J Kong C Li B Peng C Wong CC Hou F Zhang Y Mixed lineage leukemia 5 (MLL5) Protein Stability is cooperatively regulated by O-GlcNac Transferase (OGT) and Ubiquitin specific protease 7 (USP7) PLoS ONE 2015 10 12 e0145023 10.1371/journal.pone.0145023 26678539
Ding X, Jiang W, Zhou P, Liu L, Wan X, Yuan X, Wang X, Chen M, Chen J, Yang J, Kong C, Li B, Peng C, Wong CC, Hou F, Zhang Y. Mixed lineage leukemia 5 (MLL5) Protein Stability is cooperatively regulated by O-GlcNac Transferase (OGT) and Ubiquitin specific protease 7 (USP7). PLoS ONE. 2015;10(12):e0145023. 10.1371/journal.pone.0145023.26678539
27. Zhai L, Yang X, Dong J, Qian L, Gao Y, Lv Y, Chen L, Chen B, Zhou F. O–GlcNAcylation mediates endometrial cancer progression by regulating the Hippo–YAP pathway. Int J Oncol. 2023;63(2). 10.3892/ijo.2023.5538.
28. -Wang Y Wang G Liu Y Yang F Zhang H Kong Y Icaritin inhibits endometrial carcinoma cells by suppressing O-GlcNAcylation of FOXC1 Phytomedicine: Int J Phytotherapy Phytopharmacology 2023 120 155062 10.1016/j.phymed.2023.155062
Wang Y, Wang G, Liu Y, Yang F, Zhang H, Kong Y. Icaritin inhibits endometrial carcinoma cells by suppressing O-GlcNAcylation of FOXC1. Phytomedicine: Int J Phytotherapy Phytopharmacology. 2023;120:155062. 10.1016/j.phymed.2023.155062.
29. -Poulose N Forsythe N Polonski A Gregg G Maguire S Fuchs M Minner S Sauter G McDade SS Mills IG VPRBP functions downstream of the androgen receptor and OGT to restrict p53 activation in prostate Cancer Mol cancer Research: MCR 2022 20 7 1047 60 10.1158/1541-7786.Mcr-21-0477 35348747
Poulose N, Forsythe N, Polonski A, Gregg G, Maguire S, Fuchs M, Minner S, Sauter G, McDade SS, Mills IG. VPRBP functions downstream of the androgen receptor and OGT to restrict p53 activation in prostate Cancer. Mol cancer Research: MCR. 2022;20(7):1047–60. 10.1158/1541-7786.Mcr-21-0477.35348747
30. -Shen H Zhao X Chen J Qu W Huang X Wang M Shao Z Shu Q Li X O-GlcNAc transferase ogt regulates embryonic neuronal development through modulating Wnt/β-catenin signaling Hum Mol Genet 2021 31 1 57 68 10.1093/hmg/ddab223 34346496
Shen H, Zhao X, Chen J, Qu W, Huang X, Wang M, Shao Z, Shu Q, Li X. O-GlcNAc transferase ogt regulates embryonic neuronal development through modulating Wnt/β-catenin signaling. Hum Mol Genet. 2021;31(1):57–68. 10.1093/hmg/ddab223.34346496
31. Levine ZG, Potter SC, Joiner CM, Fei GQ, Nabet B, Sonnett M, Zachara NE, Gray NS, Paulo JA, Walker S. Mammalian cell proliferation requires noncatalytic functions of O-GlcNAc transferase. Proc Natl Acad Sci USA. 2021;118(4). 10.1073/pnas.2016778118.
32. -Li X Yue X Sepulveda H Burt RA Scott DA AC SAM Rao A OGT controls mammalian cell viability by regulating the proteasome/mTOR/ mitochondrial axis Proc Natl Acad Sci USA 2023 120 3 e2218332120 10.1073/pnas.2218332120 36626549
Li X, Yue X, Sepulveda H, Burt RA, Scott DA, S, AC SAM, Rao A. OGT controls mammalian cell viability by regulating the proteasome/mTOR/ mitochondrial axis. Proc Natl Acad Sci USA. 2023;120(3):e2218332120. 10.1073/pnas.2218332120.36626549
33. -Liu F Shi J Tanimukai H Gu J Gu J Grundke-Iqbal I Iqbal K Gong CX Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer’s disease Brain 2009 132 Pt 7 1820 32 10.1093/brain/awp099 19451179
Liu F, Shi J, Tanimukai H, Gu J, Gu J, Grundke-Iqbal I, Iqbal K, Gong CX. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer’s disease. Brain. 2009;132(Pt 7):1820–32. 10.1093/brain/awp099.19451179
34. -Zhang X Qiao Y Wu Q Chen Y Zou S Liu X Zhu G Zhao Y Chen Y Yu Y Pan Q Wang J Sun F The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis Nat Commun 2017 8 15280 10.1038/ncomms15280 28474680
Zhang X, Qiao Y, Wu Q, Chen Y, Zou S, Liu X, Zhu G, Zhao Y, Chen Y, Yu Y, Pan Q, Wang J, Sun F. The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis. Nat Commun. 2017;8:15280. 10.1038/ncomms15280.28474680
35. -Jiang M Qiu Z Zhang S Fan X Cai X Xu B Li X Zhou J Zhang X Chu Y Wang W Liang J Horvath T Yang X Wu K Nie Y Fan D Elevated O-GlcNAcylation promotes gastric cancer cells proliferation by modulating cell cycle related proteins and ERK 1/2 signaling Oncotarget 2016 7 38 61390 402 10.18632/oncotarget.11359 27542217
Jiang M, Qiu Z, Zhang S, Fan X, Cai X, Xu B, Li X, Zhou J, Zhang X, Chu Y, Wang W, Liang J, Horvath T, Yang X, Wu K, Nie Y, Fan D. Elevated O-GlcNAcylation promotes gastric cancer cells proliferation by modulating cell cycle related proteins and ERK 1/2 signaling. Oncotarget. 2016;7(38):61390–402. 10.18632/oncotarget.11359.27542217
36. -Zhu G Qian M Lu L Chen Y Zhang X Wu Q Liu Y Bian Z Yang Y Guo S Wang J Pan Q Sun F O-GlcNAcylation of YY1 stimulates tumorigenesis in colorectal cancer cells by targeting SLC22A15 and AANAT Carcinogenesis 2019 40 9 1121 31 10.1093/carcin/bgz010 30715269
Zhu G, Qian M, Lu L, Chen Y, Zhang X, Wu Q, Liu Y, Bian Z, Yang Y, Guo S, Wang J, Pan Q, Sun F. O-GlcNAcylation of YY1 stimulates tumorigenesis in colorectal cancer cells by targeting SLC22A15 and AANAT. Carcinogenesis. 2019;40(9):1121–31. 10.1093/carcin/bgz010.30715269
37. -Shi R Tao J Jiang X Li M Zhu R Luo S Lu Z Fructose-1,6-bisphosphatase 1 suppresses PPARα-mediated gene transcription and non-small-cell lung cancer progression Am J cancer Res 2023 13 10 4742 54 37970353
Shi R, Tao J, Jiang X, Li M, Zhu R, Luo S, Lu Z. Fructose-1,6-bisphosphatase 1 suppresses PPARα-mediated gene transcription and non-small-cell lung cancer progression. Am J cancer Res. 2023;13(10):4742–54.37970353
38. -Wang Z Li M Jiang H Luo S Shao F Xia Y Yang M Ren X Liu T Yan M Qian X He H Guo D Duan Y Wu K Wang L Ji G Shen Y Li L Zheng P Dong B Fang J Zheng M Liang T Li H Yu R Xu D Lu Z Fructose-1,6-bisphosphatase 1 functions as a protein phosphatase to dephosphorylate histone H3 and suppresses PPARα-regulated gene transcription and tumour growth Nat Cell Biol 2022 24 11 1655 65 10.1038/s41556-022-01009-4 36266488
Wang Z, Li M, Jiang H, Luo S, Shao F, Xia Y, Yang M, Ren X, Liu T, Yan M, Qian X, He H, Guo D, Duan Y, Wu K, Wang L, Ji G, Shen Y, Li L, Zheng P, Dong B, Fang J, Zheng M, Liang T, Li H, Yu R, Xu D, Lu Z. Fructose-1,6-bisphosphatase 1 functions as a protein phosphatase to dephosphorylate histone H3 and suppresses PPARα-regulated gene transcription and tumour growth. Nat Cell Biol. 2022;24(11):1655–65. 10.1038/s41556-022-01009-4.36266488
39. Yin Q, Zheng M, Luo Q, Jiang D, Zhang H, Chen C. YB-1 as an oncoprotein: functions, Regulation, post-translational modifications, and targeted therapy. Cells. 2022;11(7). 10.3390/cells11071217.
40. -Tao Z Ruan H Sun L Kuang D Song Y Wang Q Wang T Hao Y Chen K Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity Cancer Immunol Res 2019 7 7 1135 47 10.1158/2326-6066.Cir-18-0648 31113805
Tao Z, Ruan H, Sun L, Kuang D, Song Y, Wang Q, Wang T, Hao Y, Chen K. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity. Cancer Immunol Res. 2019;7(7):1135–47. 10.1158/2326-6066.Cir-18-0648.31113805
41. -Liu Q Tao T Liu F Ni R Lu C Shen A Hyper-O-GlcNAcylation of YB-1 affects Ser102 phosphorylation and promotes cell proliferation in hepatocellular carcinoma Exp Cell Res 2016 349 2 230 8 10.1016/j.yexcr.2016.10.011 27751836
Liu Q, Tao T, Liu F, Ni R, Lu C, Shen A. Hyper-O-GlcNAcylation of YB-1 affects Ser102 phosphorylation and promotes cell proliferation in hepatocellular carcinoma. Exp Cell Res. 2016;349(2):230–8. 10.1016/j.yexcr.2016.10.011.27751836
42. -Zhou P Chang WY Gong DA Xia J Chen W Huang LY Liu R Liu Y Chen C Wang K Tang N Huang AL High dietary fructose promotes hepatocellular carcinoma progression by enhancing O-GlcNAcylation via microbiota-derived acetate Cell Metabol 2023 35 11 1961 75 10.1016/j.cmet.2023.09.009
Zhou P, Chang WY, Gong DA, Xia J, Chen W, Huang LY, Liu R, Liu Y, Chen C, Wang K, Tang N, Huang AL. High dietary fructose promotes hepatocellular carcinoma progression by enhancing O-GlcNAcylation via microbiota-derived acetate. Cell Metabol. 2023;35(11):1961–75. .e6.
43. -Ullah R Yin Q Snell AH Wan L RAF-MEK-ERK pathway in cancer evolution and treatment Sem Cancer Biol 2022 85 123 54 10.1016/j.semcancer.2021.05.010
Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK pathway in cancer evolution and treatment. Sem Cancer Biol. 2022;85:123–54. 10.1016/j.semcancer.2021.05.010.
44. -Xu Y Sheng X Zhao T Zhang L Ruan Y Lu H O-GlcNAcylation of MEK2 promotes the proliferation and migration of breast cancer cells Glycobiology 2021 31 5 571 81 10.1093/glycob/cwaa103 33226073
Xu Y, Sheng X, Zhao T, Zhang L, Ruan Y, Lu H. O-GlcNAcylation of MEK2 promotes the proliferation and migration of breast cancer cells. Glycobiology. 2021;31(5):571–81. 10.1093/glycob/cwaa103.33226073
45. -Chai Y Du Y Zhang S Xiao J Luo Z He F Huang K MicroRNA-485-5p reduces O-GlcNAcylation of Bmi-1 and inhibits colorectal cancer proliferation Exp Cell Res 2018 368 1 111 8 10.1016/j.yexcr.2018.04.020 29680296
Chai Y, Du Y, Zhang S, Xiao J, Luo Z, He F, Huang K. MicroRNA-485-5p reduces O-GlcNAcylation of Bmi-1 and inhibits colorectal cancer proliferation. Exp Cell Res. 2018;368(1):111–8. 10.1016/j.yexcr.2018.04.020.29680296
46. -Li J Ahmad M Sang L Zhan Y Wang Y Yan Y Liu Y Mi W Lu M Dai Y Zhang R Dong MQ Yang YG Wang X Sun J Li J O-GlcNAcylation promotes the cytosolic localization of the m(6)a reader YTHDF1 and colorectal cancer tumorigenesis J Biol Chem 2023 299 6 104738 10.1016/j.jbc.2023.104738 37086786
Li J, Ahmad M, Sang L, Zhan Y, Wang Y, Yan Y, Liu Y, Mi W, Lu M, Dai Y, Zhang R, Dong MQ, Yang YG, Wang X, Sun J, Li J. O-GlcNAcylation promotes the cytosolic localization of the m(6)a reader YTHDF1 and colorectal cancer tumorigenesis. J Biol Chem. 2023;299(6):104738. 10.1016/j.jbc.2023.104738.37086786
47. -Su Z Gao A Li X Zou S He C Wu J Ding WQ Zhou J DNA polymerase Iota promotes esophageal squamous cell Carcinoma Proliferation through Erk-OGT-Induced G6PD overactivation Front Oncol 2021 11 706337 10.3389/fonc.2021.706337 34354953
Su Z, Gao A, Li X, Zou S, He C, Wu J, Ding WQ, Zhou J. DNA polymerase Iota promotes esophageal squamous cell Carcinoma Proliferation through Erk-OGT-Induced G6PD overactivation. Front Oncol. 2021;11:706337. 10.3389/fonc.2021.706337.34354953
48. -Yu FY Zhou CY Liu YB Wang B Mao L Li Y miR-483 is down-regulated in gastric cancer and suppresses cell proliferation, invasion and protein O-GlcNAcylation by targeting OGT Neoplasma 2018 65 3 406 14 10.4149/neo_2018_170608N411 29788742
Yu FY, Zhou CY, Liu YB, Wang B, Mao L, Li Y. miR-483 is down-regulated in gastric cancer and suppresses cell proliferation, invasion and protein O-GlcNAcylation by targeting OGT. Neoplasma. 2018;65(3):406–14. 10.4149/neo_2018_170608N411.29788742
49. -Ning D Chen J Du P Liu Q Cheng Q Li X Zhang B Chen X Jiang L The crosstalk network of XIST/miR-424-5p/OGT mediates RAF1 glycosylation and participates in the progression of liver cancer Liver International: Official J Int Association Study Liver 2021 41 8 1933 44 10.1111/liv.14904
Ning D, Chen J, Du P, Liu Q, Cheng Q, Li X, Zhang B, Chen X, Jiang L. The crosstalk network of XIST/miR-424-5p/OGT mediates RAF1 glycosylation and participates in the progression of liver cancer. Liver International: Official J Int Association Study Liver. 2021;41(8):1933–44. 10.1111/liv.14904.
50. -Zheng W Li H Zhang H Zhang C Zhu Z Liang H Zhou Y Long noncoding RNA RHPN1-AS1 promotes colorectal cancer progression via targeting miR-7-5p/OGT axis Cancer Cell Int 2020 20 54 10.1186/s12935-020-1110-9 32099527
Zheng W, Li H, Zhang H, Zhang C, Zhu Z, Liang H, Zhou Y. Long noncoding RNA RHPN1-AS1 promotes colorectal cancer progression via targeting miR-7-5p/OGT axis. Cancer Cell Int. 2020;20:54. 10.1186/s12935-020-1110-9.32099527
51. -Gerstberger S Jiang Q Ganesh K Metastasis Cell 2023 186 8 1564 79 10.1016/j.cell.2023.03.003 37059065
Gerstberger S, Jiang Q, Ganesh K, Metastasis. Cell. 2023;186(8):1564–79. 10.1016/j.cell.2023.03.003.37059065
52. -Mittal V Epithelial mesenchymal transition in Tumor Metastasis Annu Rev Pathol 2018 13 395 412 10.1146/annurev-pathol-020117-043854 29414248
Mittal V. Epithelial mesenchymal transition in Tumor Metastasis. Annu Rev Pathol. 2018;13:395–412. 10.1146/annurev-pathol-020117-043854.29414248
53. -Dongre A Weinberg RA New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer Nat Rev Mol Cell Biol 2019 20 2 69 84 10.1038/s41580-018-0080-4 30459476
Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84. 10.1038/s41580-018-0080-4.30459476
54. -Jiang M Xu B Li X Shang Y Chu Y Wang W Chen D Wu N Hu S Zhang S Li M Wu K Yang X Liang J Nie Y Fan D O-GlcNAcylation promotes colorectal cancer metastasis via the miR-101-O-GlcNAc/EZH2 regulatory feedback circuit Oncogene 2019 38 3 301 16 10.1038/s41388-018-0435-5 30093632
Jiang M, Xu B, Li X, Shang Y, Chu Y, Wang W, Chen D, Wu N, Hu S, Zhang S, Li M, Wu K, Yang X, Liang J, Nie Y, Fan D. O-GlcNAcylation promotes colorectal cancer metastasis via the miR-101-O-GlcNAc/EZH2 regulatory feedback circuit. Oncogene. 2019;38(3):301–16. 10.1038/s41388-018-0435-5.30093632
55. -Ge X Peng X Li M Ji F Chen J Zhang D OGT regulated O-GlcNacylation promotes migration and invasion by activating IL-6/STAT3 signaling in NSCLC cells Pathol Res Pract 2021 225 153580 10.1016/j.prp.2021.153580 34391182
Ge X, Peng X, Li M, Ji F, Chen J, Zhang D. OGT regulated O-GlcNacylation promotes migration and invasion by activating IL-6/STAT3 signaling in NSCLC cells. Pathol Res Pract. 2021;225:153580. 10.1016/j.prp.2021.153580.34391182
56. -Jin FZ Yu C Zhao DZ Wu MJ Yang Z A correlation between altered O-GlcNAcylation, migration and with changes in E-cadherin levels in ovarian cancer cells Exp Cell Res 2013 319 10 1482 90 10.1016/j.yexcr.2013.03.013 23524144
Jin FZ, Yu C, Zhao DZ, Wu MJ, Yang Z. A correlation between altered O-GlcNAcylation, migration and with changes in E-cadherin levels in ovarian cancer cells. Exp Cell Res. 2013;319(10):1482–90. 10.1016/j.yexcr.2013.03.013.23524144
57. -de Almeida LGN Thode H Eslambolchi Y Chopra S Young D Gill S Devel L Dufour A Matrix metalloproteinases: from Molecular mechanisms to Physiology, Pathophysiology, and Pharmacology Pharmacol Rev 2022 74 3 712 68 10.1124/pharmrev.121.000349 35738680
de Almeida LGN, Thode H, Eslambolchi Y, Chopra S, Young D, Gill S, Devel L, Dufour A. Matrix metalloproteinases: from Molecular mechanisms to Physiology, Pathophysiology, and Pharmacology. Pharmacol Rev. 2022;74(3):712–68. 10.1124/pharmrev.121.000349.35738680
58. -Zitka O Kukacka J Krizkova S Huska D Adam V Masarik M Prusa R Kizek R Matrix metalloproteinases Curr Med Chem 2010 17 31 3751 68 10.2174/092986710793213724 20846107
Zitka O, Kukacka J, Krizkova S, Huska D, Adam V, Masarik M, Prusa R, Kizek R. Matrix metalloproteinases. Curr Med Chem. 2010;17(31):3751–68. 10.2174/092986710793213724.20846107
59. -Kessenbrock K Plaks V Werb Z Matrix metalloproteinases: regulators of the tumor microenvironment Cell 2010 141 1 52 67 10.1016/j.cell.2010.03.015 20371345
Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67. 10.1016/j.cell.2010.03.015.20371345
60. -Qiao Z Dang C Zhou B Li S Zhang W Jiang J Zhang J Ma Y Kong R Ma Z Downregulation of O-linked N-acetylglucosamine transferase by RNA interference decreases MMP9 expression in human esophageal cancer cells Oncol Lett 2016 11 5 3317 23 10.3892/ol.2016.4428 27123109
Qiao Z, Dang C, Zhou B, Li S, Zhang W, Jiang J, Zhang J, Ma Y, Kong R, Ma Z. Downregulation of O-linked N-acetylglucosamine transferase by RNA interference decreases MMP9 expression in human esophageal cancer cells. Oncol Lett. 2016;11(5):3317–23. 10.3892/ol.2016.4428.27123109
61. -Lynch TP Ferrer CM Jackson SR Shahriari KS Vosseller K Reginato MJ Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis J Biol Chem 2012 287 14 11070 81 10.1074/jbc.M111.302547 22275356
Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, Reginato MJ. Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem. 2012;287(14):11070–81. 10.1074/jbc.M111.302547.22275356
62. -Li X Wu Z He J Jin Y Chu C Cao Y Gu F Wang H Hou C Liu X Zou Q OGT regulated O-GlcNAcylation promotes papillary thyroid cancer malignancy via activating YAP Oncogene 2021 40 30 4859 71 10.1038/s41388-021-01901-7 34155345
Li X, Wu Z, He J, Jin Y, Chu C, Cao Y, Gu F, Wang H, Hou C, Liu X, Zou Q. OGT regulated O-GlcNAcylation promotes papillary thyroid cancer malignancy via activating YAP. Oncogene. 2021;40(30):4859–71. 10.1038/s41388-021-01901-7.34155345
63. -Lv Z Ma G Zhong Z Xie X Li B Long D O-GlcNAcylation of RAB10 promotes hepatocellular carcinoma progression Carcinogenesis 2023 44 10–11 785 94 10.1093/carcin/bgad034 37218374
Lv Z, Ma G, Zhong Z, Xie X, Li B, Long D. O-GlcNAcylation of RAB10 promotes hepatocellular carcinoma progression. Carcinogenesis. 2023;44(10–11):785–94. 10.1093/carcin/bgad034.37218374
64. -Hao JW Wang J Guo H Zhao YY Sun HH Li YF Lai XY Zhao N Wang X Xie C Hong L Huang X Wang HR Li CB Liang B Chen S Zhao TJ CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis Nat Commun 2020 11 1 4765 10.1038/s41467-020-18565-8 32958780
Hao JW, Wang J, Guo H, Zhao YY, Sun HH, Li YF, Lai XY, Zhao N, Wang X, Xie C, Hong L, Huang X, Wang HR, Li CB, Liang B, Chen S, Zhao TJ. CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis. Nat Commun. 2020;11(1):4765. 10.1038/s41467-020-18565-8.32958780
65. -Son NH Basu D Samovski D Pietka TA Peche VS Willecke F Fang X Yu SQ Scerbo D Chang HR Sun F Bagdasarov S Drosatos K Yeh ST Mullick AE Shoghi KI Gumaste N Kim K Huggins LA Lhakhang T Abumrad NA Goldberg IJ Endothelial cell CD36 optimizes tissue fatty acid uptake J Clin Investig 2018 128 10 4329 42 10.1172/jci99315 30047927
Son NH, Basu D, Samovski D, Pietka TA, Peche VS, Willecke F, Fang X, Yu SQ, Scerbo D, Chang HR, Sun F, Bagdasarov S, Drosatos K, Yeh ST, Mullick AE, Shoghi KI, Gumaste N, Kim K, Huggins LA, Lhakhang T, Abumrad NA, Goldberg IJ. Endothelial cell CD36 optimizes tissue fatty acid uptake. J Clin Investig. 2018;128(10):4329–42. 10.1172/jci99315.30047927
66. -Jiang M Wu N Xu B Chu Y Li X Su S Chen D Li W Shi Y Gao X Zhang H Zhang Z Du W Nie Y Liang J Fan D Fatty acid-induced CD36 expression via O-GlcNAcylation drives gastric cancer metastasis Theranostics 2019 9 18 5359 73 10.7150/thno.34024 31410220
Jiang M, Wu N, Xu B, Chu Y, Li X, Su S, Chen D, Li W, Shi Y, Gao X, Zhang H, Zhang Z, Du W, Nie Y, Liang J, Fan D. Fatty acid-induced CD36 expression via O-GlcNAcylation drives gastric cancer metastasis. Theranostics. 2019;9(18):5359–73. 10.7150/thno.34024.31410220
67. -Wang X Lu Z Gomez A Hon GC Yue Y Han D Fu Y Parisien M Dai Q Jia G Ren B Pan T He C N6-methyladenosine-dependent regulation of messenger RNA stability Nature 2014 505 7481 117 20 10.1038/nature12730 24284625
Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Fu Y, Parisien M, Dai Q, Jia G, Ren B, Pan T, He C. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117–20. 10.1038/nature12730.24284625
68. -Lee Y Choe J Park OH Kim YK Molecular mechanisms driving mRNA degradation by m(6)a modification Trends Genet 2020 36 3 177 88 10.1016/j.tig.2019.12.007 31964509
Lee Y, Choe J, Park OH, Kim YK. Molecular mechanisms driving mRNA degradation by m(6)a modification. Trends Genet. 2020;36(3):177–88. 10.1016/j.tig.2019.12.007.31964509
69. -Yang Y Yan Y Yin J Tang N Wang K Huang L Hu J Feng Z Gao Q Huang A O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N(6)-methyladenosine-dependent manner Signal Transduct Target Therapy 2023 8 1 63 10.1038/s41392-023-01316-8
Yang Y, Yan Y, Yin J, Tang N, Wang K, Huang L, Hu J, Feng Z, Gao Q, Huang A. O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N(6)-methyladenosine-dependent manner. Signal Transduct Target Therapy. 2023;8(1):63. 10.1038/s41392-023-01316-8.
70. -Wang G Xu Z Sun J Liu B Ruan Y Gu J Song S O-GlcNAcylation enhances Reticulon 2 protein stability and its promotive effects on gastric cancer progression Cell Signal 2023 108 110718 10.1016/j.cellsig.2023.110718 37196774
Wang G, Xu Z, Sun J, Liu B, Ruan Y, Gu J, Song S. O-GlcNAcylation enhances Reticulon 2 protein stability and its promotive effects on gastric cancer progression. Cell Signal. 2023;108:110718. 10.1016/j.cellsig.2023.110718.37196774
71. Lin CH, Liao CC, Wang SY, Peng CY, Yeh YC, Chen MY, Chou TY. Comparative O-GlcNAc proteomic analysis reveals a role of O-GlcNAcylated SAM68 in Lung Cancer aggressiveness. Cancers. 2022;14(1). 10.3390/cancers14010243.
72. -Liu HY Liu YY Yang F Zhang L Zhang FL Hu X Shao ZM Li DQ Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer Nucleic Acids Res 2020 48 7 3638 56 10.1093/nar/gkaa130 32112098
Liu HY, Liu YY, Yang F, Zhang L, Zhang FL, Hu X, Shao ZM, Li DQ. Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer. Nucleic Acids Res. 2020;48(7):3638–56. 10.1093/nar/gkaa130.32112098
73. -Zhang FL Yang SY Liao L Zhang TM Zhang YL Hu SY Deng L Huang MY Andriani L Ma XY Shao ZM Li DQ Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer Theranostics 2023 13 3 973 90 10.7150/thno.79688 36793866
Zhang FL, Yang SY, Liao L, Zhang TM, Zhang YL, Hu SY, Deng L, Huang MY, Andriani L, Ma XY, Shao ZM, Li DQ. Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer. Theranostics. 2023;13(3):973–90. 10.7150/thno.79688.36793866
74. -Liu YY Liu HY Yu TJ Lu Q Zhang FL Liu GY Shao ZM Li DQ O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-β signaling to breast cancer progression Cell Death Differ 2022 29 4 861 73 10.1038/s41418-021-00901-0 34974534
Liu YY, Liu HY, Yu TJ, Lu Q, Zhang FL, Liu GY, Shao ZM, Li DQ. O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-β signaling to breast cancer progression. Cell Death Differ. 2022;29(4):861–73. 10.1038/s41418-021-00901-0.34974534
75. -Caldwell SA Jackson SR Shahriari KS Lynch TP Sethi G Walker S Vosseller K Reginato MJ Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1 Oncogene 2010 29 19 2831 42 10.1038/onc.2010.41 20190804
Caldwell SA, Jackson SR, Shahriari KS, Lynch TP, Sethi G, Walker S, Vosseller K, Reginato MJ. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene. 2010;29(19):2831–42. 10.1038/onc.2010.41.20190804
76. -Liu Y Huang H Cao Y Wu Q Li W Zhang J Suppression of OGT by microRNA24 reduces FOXA1 stability and prevents breast cancer cells invasion Biochem Biophys Res Commun 2017 487 3 755 62 10.1016/j.bbrc.2017.04.135 28455227
Liu Y, Huang H, Cao Y, Wu Q, Li W, Zhang J. Suppression of OGT by microRNA24 reduces FOXA1 stability and prevents breast cancer cells invasion. Biochem Biophys Res Commun. 2017;487(3):755–62. 10.1016/j.bbrc.2017.04.135.28455227
77. -Tao T He Z Shao Z Lu H Table 3 O-GlcNAcylation promotes metastasis of triple negative breast cancer Oncotarget 2016 7 16 22807 18 10.18632/oncotarget.8182 27009840
Tao T, He Z, Shao Z, Lu H. Table 3 O-GlcNAcylation promotes metastasis of triple negative breast cancer. Oncotarget. 2016;7(16):22807–18. 10.18632/oncotarget.8182.27009840
78. -Mirzaei S Saghari S Bassiri F Raesi R Zarrabi A Hushmandi K Sethi G Tergaonkar V NF-κB as a regulator of cancer metastasis and therapy response: a focus on epithelial-mesenchymal transition J Cell Physiol 2022 237 7 2770 95 10.1002/jcp.30759 35561232
Mirzaei S, Saghari S, Bassiri F, Raesi R, Zarrabi A, Hushmandi K, Sethi G, Tergaonkar V. NF-κB as a regulator of cancer metastasis and therapy response: a focus on epithelial-mesenchymal transition. J Cell Physiol. 2022;237(7):2770–95. 10.1002/jcp.30759.35561232
79. -Mortezaee K Najafi M Farhood B Ahmadi A Shabeeb D Musa AE NF-κB targeting for overcoming tumor resistance and normal tissues toxicity J Cell Physiol 2019 234 10 17187 204 10.1002/jcp.28504 30912132
Mortezaee K, Najafi M, Farhood B, Ahmadi A, Shabeeb D, Musa AE. NF-κB targeting for overcoming tumor resistance and normal tissues toxicity. J Cell Physiol. 2019;234(10):17187–204. 10.1002/jcp.28504.30912132
80. -Ali A Kim SH Kim MJ Choi MY Kang SS Cho GJ Kim YS Choi JY Choi WS O-GlcNAcylation of NF-κB promotes Lung Metastasis of Cervical Cancer cells via Upregulation of CXCR4 expression Mol Cells 2017 40 7 476 84 10.14348/molcells.2017.2309 28681591
Ali A, Kim SH, Kim MJ, Choi MY, Kang SS, Cho GJ, Kim YS, Choi JY, Choi WS. O-GlcNAcylation of NF-κB promotes Lung Metastasis of Cervical Cancer cells via Upregulation of CXCR4 expression. Mol Cells. 2017;40(7):476–84. 10.14348/molcells.2017.2309.28681591
81. -Niu Y Xia Y Wang J Shi X O-GlcNAcylation promotes migration and invasion in human ovarian cancer cells via the RhoA/ROCK/MLC pathway Mol Med Rep 2017 15 4 2083 9 10.3892/mmr.2017.6244 28259907
Niu Y, Xia Y, Wang J, Shi X. O-GlcNAcylation promotes migration and invasion in human ovarian cancer cells via the RhoA/ROCK/MLC pathway. Mol Med Rep. 2017;15(4):2083–9. 10.3892/mmr.2017.6244.28259907
82. -Seo HG Kim HB Yoon JY Kweon TH Park YS Kang J Jung J Son S Yi EC Lee TH Yang WH Cho JW Mutual regulation between OGT and XIAP to control colon cancer cell growth and invasion Cell Death Dis 2020 11 9 815 10.1038/s41419-020-02999-5 32994395
Seo HG, Kim HB, Yoon JY, Kweon TH, Park YS, Kang J, Jung J, Son S, Yi EC, Lee TH, Yang WH, Cho JW. Mutual regulation between OGT and XIAP to control colon cancer cell growth and invasion. Cell Death Dis. 2020;11(9):815. 10.1038/s41419-020-02999-5.32994395
83. -Wu N Jiang M Han Y Liu H Chu Y Liu H Cao J Hou Q Zhao Y Xu B Xie X O-GlcNAcylation promotes colorectal cancer progression by regulating protein stability and potential catcinogenic function of DDX5 J Cell Mol Med 2019 23 2 1354 62 10.1111/jcmm.14038 30484950
Wu N, Jiang M, Han Y, Liu H, Chu Y, Liu H, Cao J, Hou Q, Zhao Y, Xu B, Xie X. O-GlcNAcylation promotes colorectal cancer progression by regulating protein stability and potential catcinogenic function of DDX5. J Cell Mol Med. 2019;23(2):1354–62. 10.1111/jcmm.14038.30484950
84. -Huang X Pan Q Sun D Chen W Shen A Huang M Ding J Geng M O-GlcNAcylation of cofilin promotes breast cancer cell invasion J Biol Chem 2013 288 51 36418 25 10.1074/jbc.M113.495713 24214978
Huang X, Pan Q, Sun D, Chen W, Shen A, Huang M, Ding J, Geng M. O-GlcNAcylation of cofilin promotes breast cancer cell invasion. J Biol Chem. 2013;288(51):36418–25. 10.1074/jbc.M113.495713.24214978
85. -Wang L Li G Zhou Z Ge C Chen Q Liu Y Zhang N Zhang K Niu M Li W Zhong X Wu S Zhang J Liu Y Chromatin-associated OGT promotes the malignant progression of hepatocellular carcinoma by activating ZNF263 Oncogene 2023 42 30 2329 46 10.1038/s41388-023-02751-1 37353617
Wang L, Li G, Zhou Z, Ge C, Chen Q, Liu Y, Zhang N, Zhang K, Niu M, Li W, Zhong X, Wu S, Zhang J, Liu Y. Chromatin-associated OGT promotes the malignant progression of hepatocellular carcinoma by activating ZNF263. Oncogene. 2023;42(30):2329–46. 10.1038/s41388-023-02751-1.37353617
86. -Zhu G Tao T Zhang D Liu X Qiu H Han L Xu Z Xiao Y Cheng C Shen A O-GlcNAcylation of histone deacetylases 1 in hepatocellular carcinoma promotes cancer progression Glycobiology 2016 26 8 820 33 10.1093/glycob/cww025 27060025
Zhu G, Tao T, Zhang D, Liu X, Qiu H, Han L, Xu Z, Xiao Y, Cheng C, Shen A. O-GlcNAcylation of histone deacetylases 1 in hepatocellular carcinoma promotes cancer progression. Glycobiology. 2016;26(8):820–33. 10.1093/glycob/cww025.27060025
87. -Stine ZE Schug ZT Salvino JM Dang CV Targeting cancer metabolism in the era of precision oncology Nat Rev Drug Discovery 2022 21 2 141 62 10.1038/s41573-021-00339-6 34862480
Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discovery. 2022;21(2):141–62. 10.1038/s41573-021-00339-6.34862480
88. -Yu T Wang Y Fan Y Fang N Wang T Xu T Shu Y CircRNAs in cancer metabolism: a review J Hematol Oncol 2019 12 1 90 10.1186/s13045-019-0776-8 31484561
Yu T, Wang Y, Fan Y, Fang N, Wang T, Xu T, Shu Y. CircRNAs in cancer metabolism: a review. J Hematol Oncol. 2019;12(1):90. 10.1186/s13045-019-0776-8.31484561
89. -Mikawa T ME LL Takaori-Kondo A Inagaki N Yokode M Kondoh H Dysregulated glycolysis as an oncogenic event Cell Mol Life Sci 2015 72 10 1881 92 10.1007/s00018-015-1840-3 25609364
Mikawa T, ME LL, Takaori-Kondo A, Inagaki N, Yokode M, Kondoh H. Dysregulated glycolysis as an oncogenic event. Cell Mol Life Sci. 2015;72(10):1881–92. 10.1007/s00018-015-1840-3.25609364
90. -Hu H Zhu W Qin J Chen M Gong L Li L Liu X Tao Y Yin H Zhou H Zhou L Ye D Ye Q Gao D Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis Hepatology (Baltimore MD) 2017 65 2 515 28 10.1002/hep.28887 27774669
Hu H, Zhu W, Qin J, Chen M, Gong L, Li L, Liu X, Tao Y, Yin H, Zhou H, Zhou L, Ye D, Ye Q, Gao D. Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis. Hepatology (Baltimore MD). 2017;65(2):515–28. 10.1002/hep.28887.27774669
91. -He Y Wang X Lu W Zhang D Huang L Luo Y Xiong L Li H Zhang P Li Q Liang S PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis Cell Death Dis 2022 13 2 118 10.1038/s41419-022-04576-4 35121728
He Y, Wang X, Lu W, Zhang D, Huang L, Luo Y, Xiong L, Li H, Zhang P, Li Q, Liang S. PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. Cell Death Dis. 2022;13(2):118. 10.1038/s41419-022-04576-4.35121728
92. -Liang J Liu C Xu D Xie K Li A LncRNA NEAT1 facilitates glioma progression via stabilizing PGK1 J Translational Med 2022 20 1 80 10.1186/s12967-022-03273-2
Liang J, Liu C, Xu D, Xie K, Li A. LncRNA NEAT1 facilitates glioma progression via stabilizing PGK1. J Translational Med. 2022;20(1):80. 10.1186/s12967-022-03273-2.
93. -Nie H Ju H Fan J Shi X Cheng Y Cang X Zheng Z Duan X Yi W O-GlcNAcylation of PGK1 coordinates glycolysis and TCA cycle to promote tumor growth Nat Commun 2020 11 1 36 10.1038/s41467-019-13601-8 31911580
Nie H, Ju H, Fan J, Shi X, Cheng Y, Cang X, Zheng Z, Duan X, Yi W. O-GlcNAcylation of PGK1 coordinates glycolysis and TCA cycle to promote tumor growth. Nat Commun. 2020;11(1):36. 10.1038/s41467-019-13601-8.31911580
94. Singh JP, Qian K, Lee JS, Zhou J, Han X, Zhang B, Ong Q, Ni W, Jiang M, Ruan HB, Li MD, Zhang K, Ding Z, Lee P, Singh K, Wu J, Herzog RI, Kaech S, Wendel HG, Yates JR 3rd, Han W, Sherwin RS, Nie Y, Yang X. O-GlcNAcase targets pyruvate kinase M2 to regulate tumor growth. Oncogene. 2020;39(3):560–73. 10.1038/s41388-019-0975-3.
95. -He X Wu N Li R Zhang H Zhao Y Nie Y Wu J IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF-κB signaling to promote colorectal cancer progression Cell Oncol (Dordrecht) 2023 46 1 145 64 10.1007/s13402-022-00740-2
He X, Wu N, Li R, Zhang H, Zhao Y, Nie Y, Wu J. IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF-κB signaling to promote colorectal cancer progression. Cell Oncol (Dordrecht). 2023;46(1):145–64. 10.1007/s13402-022-00740-2.
96. Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2021;218(1). 10.1084/jem.20201606.
97. -Bacci M Lorito N Smiriglia A Morandi A Fat and Furious: lipid metabolism in Antitumoral Therapy Response and Resistance Trends cancer 2021 7 3 198 213 10.1016/j.trecan.2020.10.004 33281098
Bacci M, Lorito N, Smiriglia A, Morandi A. Fat and Furious: lipid metabolism in Antitumoral Therapy Response and Resistance. Trends cancer. 2021;7(3):198–213. 10.1016/j.trecan.2020.10.004.33281098
98. -Guo D Bell EH Mischel P Chakravarti A Targeting SREBP-1-driven lipid metabolism to treat cancer Curr Pharm Design 2014 20 15 2619 26 10.2174/13816128113199990486
Guo D, Bell EH, Mischel P, Chakravarti A. Targeting SREBP-1-driven lipid metabolism to treat cancer. Curr Pharm Design. 2014;20(15):2619–26. 10.2174/13816128113199990486.
99. -Sodi VL Bacigalupa ZA Ferrer CM Lee JV Gocal WA Mukhopadhyay D Wellen KE Ivan M Reginato MJ Nutrient sensor O-GlcNAc transferase controls cancer lipid metabolism via SREBP-1 regulation Oncogene 2018 37 7 924 34 10.1038/onc.2017.395 29059153
Sodi VL, Bacigalupa ZA, Ferrer CM, Lee JV, Gocal WA, Mukhopadhyay D, Wellen KE, Ivan M, Reginato MJ. Nutrient sensor O-GlcNAc transferase controls cancer lipid metabolism via SREBP-1 regulation. Oncogene. 2018;37(7):924–34. 10.1038/onc.2017.395.29059153
100. -Schug ZT Vande Voorde J Gottlieb E The metabolic fate of acetate in cancer Nat Rev Cancer 2016 16 11 708 17 10.1038/nrc.2016.87 27562461
Schug ZT, Vande Voorde J, Gottlieb E. The metabolic fate of acetate in cancer. Nat Rev Cancer. 2016;16(11):708–17. 10.1038/nrc.2016.87.27562461
101. -Mashimo T Pichumani K Vemireddy V Hatanpaa KJ Singh DK Sirasanagandla S Nannepaga S Piccirillo SG Kovacs Z Foong C Huang Z Barnett S Mickey BE DeBerardinis RJ Tu BP Maher EA Bachoo RM Acetate is a bioenergetic substrate for human glioblastoma and brain metastases Cell 2014 159 7 1603 14 10.1016/j.cell.2014.11.025 25525878
Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, Nannepaga S, Piccirillo SG, Kovacs Z, Foong C, Huang Z, Barnett S, Mickey BE, DeBerardinis RJ, Tu BP, Maher EA, Bachoo RM. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 2014;159(7):1603–14. 10.1016/j.cell.2014.11.025.25525878
102. -Ciraku L Bacigalupa ZA Ju J Moeller RA Le Minh G Lee RH Smith MD Ferrer CM Trefely S Izzo LT Doan MT Gocal WA D’Agostino L Shi W Jackson JG Katsetos CD Wellen KE Snyder NW Reginato MJ O-GlcNAc transferase regulates glioblastoma acetate metabolism via regulation of CDK5-dependent ACSS2 phosphorylation Oncogene 2022 41 14 2122 36 10.1038/s41388-022-02237-6 35190642
Ciraku L, Bacigalupa ZA, Ju J, Moeller RA, Le Minh G, Lee RH, Smith MD, Ferrer CM, Trefely S, Izzo LT, Doan MT, Gocal WA, D’Agostino L, Shi W, Jackson JG, Katsetos CD, Wellen KE, Snyder NW, Reginato MJ. O-GlcNAc transferase regulates glioblastoma acetate metabolism via regulation of CDK5-dependent ACSS2 phosphorylation. Oncogene. 2022;41(14):2122–36. 10.1038/s41388-022-02237-6.35190642
103. Su KJ, Yu YL. Downregulation of SHIP2 by Hepatitis B Virus X promotes the Metastasis and Chemoresistance of Hepatocellular Carcinoma through SKP2. Cancers. 2019;11(8). 10.3390/cancers11081065.
104. -Zhang H Wang Q Liu J Cao H Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma Oncol Lett 2018 15 6 9377 84 10.3892/ol.2018.8536 29928334
Zhang H, Wang Q, Liu J, Cao H. Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma. Oncol Lett. 2018;15(6):9377–84. 10.3892/ol.2018.8536.29928334
105. -Matulonis UA Sood AK Fallowfield L Howitt BE Sehouli J Karlan BY Ovarian cancer Nat Reviews Disease Primers 2016 2 16061 10.1038/nrdp.2016.61 27558151
Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Reviews Disease Primers. 2016;2:16061. 10.1038/nrdp.2016.61.27558151
106. -Qian L Yang X Li S Zhao H Gao Y Zhao S Lv X Zhang X Li L Zhai L Zhou F Chen B Reduced O-GlcNAcylation of SNAP-23 promotes cisplatin resistance by inducing exosome secretion in ovarian cancer Cell Death Discovery 2021 7 1 112 10.1038/s41420-021-00489-x 34001861
Qian L, Yang X, Li S, Zhao H, Gao Y, Zhao S, Lv X, Zhang X, Li L, Zhai L, Zhou F, Chen B. Reduced O-GlcNAcylation of SNAP-23 promotes cisplatin resistance by inducing exosome secretion in ovarian cancer. Cell Death Discovery. 2021;7(1):112. 10.1038/s41420-021-00489-x.34001861
107. -Zhou F Yang X Zhao H Liu Y Feng Y An R Lv X Li J Chen B Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer Theranostics 2018 8 19 5200 12 10.7150/thno.27806 30555541
Zhou F, Yang X, Zhao H, Liu Y, Feng Y, An R, Lv X, Li J, Chen B. Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer. Theranostics. 2018;8(19):5200–12. 10.7150/thno.27806.30555541
108. -Huang W Chen L Zhu K Wang D Oncogenic microRNA-181d binding to OGT contributes to resistance of ovarian cancer cells to cisplatin Cell Death Discovery 2021 7 1 379 10.1038/s41420-021-00715-6 34876558
Huang W, Chen L, Zhu K, Wang D. Oncogenic microRNA-181d binding to OGT contributes to resistance of ovarian cancer cells to cisplatin. Cell Death Discovery. 2021;7(1):379. 10.1038/s41420-021-00715-6.34876558
109. -Vodenkova S Buchler T Cervena K Veskrnova V Vodicka P Vymetalkova V 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future Pharmacol Ther 2020 206 107447 10.1016/j.pharmthera.2019.107447 31756363
Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther. 2020;206:107447. 10.1016/j.pharmthera.2019.107447.31756363
110. -Longley DB Harkin DP Johnston PG 5-fluorouracil: mechanisms of action and clinical strategies Nat Rev Cancer 2003 3 5 330 8 10.1038/nrc1074 12724731
Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–8. 10.1038/nrc1074.12724731
111. -Very N Hardivillé S Decourcelle A Thévenet J Djouina M Page A Vergoten G Schulz C Kerr-Conte J Lefebvre T Dehennaut V El Yazidi-Belkoura I. Thymidylate synthase O-GlcNAcylation: a molecular mechanism of 5-FU sensitization in colorectal cancer Oncogene 2022 41 5 745 56 10.1038/s41388-021-02121-9 34845374
Very N, Hardivillé S, Decourcelle A, Thévenet J, Djouina M, Page A, Vergoten G, Schulz C, Kerr-Conte J, Lefebvre T, Dehennaut V. El Yazidi-Belkoura I. Thymidylate synthase O-GlcNAcylation: a molecular mechanism of 5-FU sensitization in colorectal cancer. Oncogene. 2022;41(5):745–56. 10.1038/s41388-021-02121-9.34845374
112. Fricker LD. Proteasome inhibitor drugs. Annu Rev Pharmacol Toxicol. 2020;60:457–76. 10.1146/annurev-pharmtox-010919-023603.
113. Sekine H, Okazaki K, Kato K, Alam MM, Shima H, Katsuoka F, Tsujita T, Suzuki N, Kobayashi A, Igarashi K, Yamamoto M, Motohashi H. O-GlcNAcylation Signal mediates proteasome inhibitor resistance in Cancer cells by stabilizing NRF1. Mol Cell Biol. 2018;38(17). 10.1128/mcb.00252-18.
114. -Shoaib Z Fan TM Irudayaraj JMK Osteosarcoma mechanobiology and therapeutic targets Br J Pharmacol 2022 179 2 201 17 10.1111/bph.15713 34679192
Shoaib Z, Fan TM, Irudayaraj JMK. Osteosarcoma mechanobiology and therapeutic targets. Br J Pharmacol. 2022;179(2):201–17. 10.1111/bph.15713.34679192
115. -Hattinger CM Tavanti E Fanelli M Vella S Picci P Serra M Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma Expert Opin Drug Metab Toxicol 2017 13 3 245 57 10.1080/17425255.2017.1246532 27758143
Hattinger CM, Tavanti E, Fanelli M, Vella S, Picci P, Serra M. Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma. Expert Opin Drug Metab Toxicol. 2017;13(3):245–57. 10.1080/17425255.2017.1246532.27758143
116. -Sun MX An HY Sun YB Sun YB Bai B LncRNA EBLN3P attributes methotrexate resistance in osteosarcoma cells through miR-200a-3p/O-GlcNAc transferase pathway J Orthop Surg Res 2022 17 1 557 10.1186/s13018-022-03449-y 36544170
Sun MX, An HY, Sun YB, Sun YB, Bai B. LncRNA EBLN3P attributes methotrexate resistance in osteosarcoma cells through miR-200a-3p/O-GlcNAc transferase pathway. J Orthop Surg Res. 2022;17(1):557. 10.1186/s13018-022-03449-y.36544170
117. -Schaeffer EM Srinivas S Adra N An Y Barocas D Bitting R Bryce A Chapin B Cheng HH D’Amico AV Desai N Dorff T Eastham JA Farrington TA Gao X Gupta S Guzzo T Ippolito JE Kuettel MR Lang JM Lotan T McKay RR Morgan T Netto G Pow-Sang JM Reiter R Roach M Robin T Rosenfeld S Shabsigh A Spratt D Teply BA Tward J Valicenti R Wong JK Shead DA Snedeker J Freedman-Cass DA Prostate Cancer, Version 4.2023, NCCN Clinical Practice guidelines in Oncology J Natl Compr Cancer Network: JNCCN 2023 21 10 1067 96 10.6004/jnccn.2023.0050 37856213
Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D’Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Shead DA, Snedeker J, Freedman-Cass DA. Prostate Cancer, Version 4.2023, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Cancer Network: JNCCN. 2023;21(10):1067–96. 10.6004/jnccn.2023.0050.37856213
118. -Xia M Wang S Qi Y Long K Li E He L Pan F Guo Z Hu Z Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel Front Oncol 2022 12 993243 10.3389/fonc.2022.993243 36439421
Xia M, Wang S, Qi Y, Long K, Li E, He L, Pan F, Guo Z, Hu Z. Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel. Front Oncol. 2022;12:993243. 10.3389/fonc.2022.993243.36439421
119. -Kamat AM Hahn NM Efstathiou JA Lerner SP Malmström PU Choi W Guo CC Lotan Y Kassouf W Bladder cancer Lancet (London England) 2016 388 10061 2796 810 10.1016/s0140-6736(16)30512-8 27345655
Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W. Bladder cancer. Lancet (London England). 2016;388(10061):2796–810. 10.1016/s0140-6736(16)30512-8.27345655
120. -Wang L Chen S Zhang Z Zhang J Mao S Zheng J Xuan Y Liu M Cai K Zhang W Guo Y Zhai W Yao X Suppressed OGT expression inhibits cell proliferation while inducing cell apoptosis in bladder cancer BMC Cancer 2018 18 1 1141 10.1186/s12885-018-5033-y 30453909
Wang L, Chen S, Zhang Z, Zhang J, Mao S, Zheng J, Xuan Y, Liu M, Cai K, Zhang W, Guo Y, Zhai W, Yao X. Suppressed OGT expression inhibits cell proliferation while inducing cell apoptosis in bladder cancer. BMC Cancer. 2018;18(1):1141. 10.1186/s12885-018-5033-y.30453909
121. -Calabrò F Lorusso V Rosati G Manzione L Frassineti L Sava T Di Paula ED Alonso S Sternberg CN Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma Cancer 2009 115 12 2652 9 10.1002/cncr.24313 19396817
Calabrò F, Lorusso V, Rosati G, Manzione L, Frassineti L, Sava T, Di Paula ED, Alonso S, Sternberg CN. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer. 2009;115(12):2652–9. 10.1002/cncr.24313.19396817
122. Lee HW, Kang MJ, Kwon YJ, Abdi Nansa S, Jung EH, Kim SH, Lee SJ, Jeong KC, Kim Y, Cheong H, Seo HK. Targeted inhibition of O-Linked β-N-Acetylglucosamine transferase as a Promising Therapeutic Strategy to Restore Chemosensitivity and Attenuate Aggressive Tumor traits in Chemoresistant Urothelial Carcinoma of the bladder. Biomedicines. 2022;10(5). 10.3390/biomedicines10051162.
123. -Kerr JF Wyllie AH Currie AR Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics Br J Cancer 1972 26 4 239 57 10.1038/bjc.1972.33 4561027
Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–57. 10.1038/bjc.1972.33.4561027
124. -Elmore S Apoptosis: a review of programmed cell death Toxicol Pathol 2007 35 4 495 516 10.1080/01926230701320337 17562483
Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516. 10.1080/01926230701320337.17562483
125. -Corcoran GB Fix L Jones DP Moslen MT Nicotera P Oberhammer FA Buttyan R Apoptosis: molecular control point in toxicity Toxicol Appl Pharmcol 1994 128 2 169 81 10.1006/taap.1994.1195
Corcoran GB, Fix L, Jones DP, Moslen MT, Nicotera P, Oberhammer FA, Buttyan R. Apoptosis: molecular control point in toxicity. Toxicol Appl Pharmcol. 1994;128(2):169–81. 10.1006/taap.1994.1195.
126. -Bold RJ Termuhlen PM McConkey DJ Apoptosis, cancer and cancer therapy Surg Oncol 1997 6 3 133 42 10.1016/s0960-7404(97)00015-7 9576629
Bold RJ, Termuhlen PM, McConkey DJ. Apoptosis, cancer and cancer therapy. Surg Oncol. 1997;6(3):133–42. 10.1016/s0960-7404(97)00015-7.9576629
127. -Evan GI Brown L Whyte M Harrington E Apoptosis and the cell cycle Curr Opin Cell Biol 1995 7 6 825 34 10.1016/0955-0674(95)80066-2 8608013
Evan GI, Brown L, Whyte M, Harrington E. Apoptosis and the cell cycle. Curr Opin Cell Biol. 1995;7(6):825–34. 10.1016/0955-0674(95)80066-2.8608013
128. -Wong RS Apoptosis in cancer: from pathogenesis to treatment J Experimental Clin cancer Research: CR 2011 30 1 87 10.1186/1756-9966-30-87
Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Experimental Clin cancer Research: CR. 2011;30(1):87. 10.1186/1756-9966-30-87.
129. -Zhou P Chang WY Gong DA Huang LY Liu R Liu Y Xia J Wang K Tang N Huang AL O-GlcNAcylation of SPOP promotes carcinogenesis in hepatocellular carcinoma Oncogene 2023 42 10 725 36 10.1038/s41388-022-02589-z 36604567
Zhou P, Chang WY, Gong DA, Huang LY, Liu R, Liu Y, Xia J, Wang K, Tang N, Huang AL. O-GlcNAcylation of SPOP promotes carcinogenesis in hepatocellular carcinoma. Oncogene. 2023;42(10):725–36. 10.1038/s41388-022-02589-z.36604567
130. -Yu M Chu S Fei B Fang X Liu Z O-GlcNAcylation of ITGA5 facilitates the occurrence and development of colorectal cancer Exp Cell Res 2019 382 2 111464 10.1016/j.yexcr.2019.06.009 31202709
Yu M, Chu S, Fei B, Fang X, Liu Z. O-GlcNAcylation of ITGA5 facilitates the occurrence and development of colorectal cancer. Exp Cell Res. 2019;382(2):111464. 10.1016/j.yexcr.2019.06.009.31202709
131. -Li Y Wang L Liu J Zhang P An M Han C Li Y Guan X Zhang K O-GlcNAcylation modulates Bmi-1 protein stability and potential oncogenic function in prostate cancer Oncogene 2017 36 45 6293 305 10.1038/onc.2017.223 28714959
Li Y, Wang L, Liu J, Zhang P, An M, Han C, Li Y, Guan X, Zhang K. O-GlcNAcylation modulates Bmi-1 protein stability and potential oncogenic function in prostate cancer. Oncogene. 2017;36(45):6293–305. 10.1038/onc.2017.223.28714959
132. -Gao S Yin H Tong H Zhan K Yang G Hossain MA Li T Gou X He W Nucleolar and Spindle Associated Protein 1 (NUSAP1) promotes bladder Cancer Progression through the TGF-β signaling pathway OncoTargets Therapy 2020 13 813 25 10.2147/ott.S237127 32099387
Gao S, Yin H, Tong H, Zhan K, Yang G, Hossain MA, Li T, Gou X, He W. Nucleolar and Spindle Associated Protein 1 (NUSAP1) promotes bladder Cancer Progression through the TGF-β signaling pathway. OncoTargets Therapy. 2020;13:813–25. 10.2147/ott.S237127.32099387
133. -Hou J Lu Z Liu X Luo B Qu G Xu Y Tang C Increased NUSAP1 expression is associated with lymph node metastasis and survival prognosis in bladder urothelial carcinoma Sci Rep 2022 12 1 7003 10.1038/s41598-022-11137-4 35487972
Hou J, Lu Z, Liu X, Luo B, Qu G, Xu Y, Tang C. Increased NUSAP1 expression is associated with lymph node metastasis and survival prognosis in bladder urothelial carcinoma. Sci Rep. 2022;12(1):7003. 10.1038/s41598-022-11137-4.35487972
134. -Chen Y Liu J Zhang W Kadier A Wang R Zhang H Yao X O-GlcNAcylation enhances NUSAP1 Stability and promotes bladder Cancer aggressiveness OncoTargets Therapy 2021 14 445 54 10.2147/ott.S258175 33488099
Chen Y, Liu J, Zhang W, Kadier A, Wang R, Zhang H, Yao X. O-GlcNAcylation enhances NUSAP1 Stability and promotes bladder Cancer aggressiveness. OncoTargets Therapy. 2021;14:445–54. 10.2147/ott.S258175.33488099
135. -Najafi M Mortezaee K Majidpoor J Cancer stem cell (CSC) resistance drivers Life Sci 2019 234 116781 10.1016/j.lfs.2019.116781 31430455
Najafi M, Mortezaee K, Majidpoor J. Cancer stem cell (CSC) resistance drivers. Life Sci. 2019;234:116781. 10.1016/j.lfs.2019.116781.31430455
136. -Kharkar PS Cancer stem cell (CSC) inhibitors: a review of recent patents (2012–2015) Expert Opin Ther Pat 2017 27 7 753 61 10.1080/13543776.2017.1325465 28460551
Kharkar PS. Cancer stem cell (CSC) inhibitors: a review of recent patents (2012–2015). Expert Opin Ther Pat. 2017;27(7):753–61. 10.1080/13543776.2017.1325465.28460551
137. -Gauthier A Ho M Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update Hepatol Research: Official J Japan Soc Hepatol 2013 43 2 147 54 10.1111/j.1872-034X.2012.01113.x
Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update. Hepatol Research: Official J Japan Soc Hepatol. 2013;43(2):147–54. 10.1111/j.1872-034X.2012.01113.x.
138. -Yuan J Lv T Yang J Wu Z Yan L Yang J Shi Y Jiang L HDLBP promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by suppressing Trim71-dependent RAF1 degradation Cell Mol Gastroenterol Hepatol 2023 15 2 307 25 10.1016/j.jcmgh.2022.10.005 36244648
Yuan J, Lv T, Yang J, Wu Z, Yan L, Yang J, Shi Y, Jiang L. HDLBP promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by suppressing Trim71-dependent RAF1 degradation. Cell Mol Gastroenterol Hepatol. 2023;15(2):307–25. 10.1016/j.jcmgh.2022.10.005.36244648
139. -Cao B Duan M Xing Y Liu C Yang F Li Y Yang T Wei Y Gao Q Jiang J O-GlcNAc transferase activates stem-like cell potential in hepatocarcinoma through O-GlcNAcylation of eukaryotic initiation factor 4E J Cell Mol Med 2019 23 4 2384 98 10.1111/jcmm.14043 30677218
Cao B, Duan M, Xing Y, Liu C, Yang F, Li Y, Yang T, Wei Y, Gao Q, Jiang J. O-GlcNAc transferase activates stem-like cell potential in hepatocarcinoma through O-GlcNAcylation of eukaryotic initiation factor 4E. J Cell Mol Med. 2019;23(4):2384–98. 10.1111/jcmm.14043.30677218
140. -Le Minh G Esquea EM Dhameliya TT Merzy J Lee MH Ball LE Reginato MJ Kruppel-like factor 8 regulates triple negative breast cancer stem cell-like activity Front Oncol 2023 13 1141834 10.3389/fonc.2023.1141834 37152043
Le Minh G, Esquea EM, Dhameliya TT, Merzy J, Lee MH, Ball LE, Reginato MJ. Kruppel-like factor 8 regulates triple negative breast cancer stem cell-like activity. Front Oncol. 2023;13:1141834. 10.3389/fonc.2023.1141834.37152043
141. -Liang C Zhang X Yang M Dong X Recent progress in Ferroptosis Inducers for Cancer Therapy. Advanced materials (Deerfield Beach Fla) 2019 31 51 e1904197 10.1002/adma.201904197
Liang C, Zhang X, Yang M, Dong X. Recent progress in Ferroptosis Inducers for Cancer Therapy. Advanced materials (Deerfield Beach. Fla). 2019;31(51):e1904197. 10.1002/adma.201904197.
142. -Jiang X Stockwell BR Conrad M Ferroptosis: mechanisms, biology and role in disease Nat Rev Mol Cell Biol 2021 22 4 266 82 10.1038/s41580-020-00324-8 33495651
Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266–82. 10.1038/s41580-020-00324-8.33495651
143. -Wu X Li Y Zhang S Zhou X Ferroptosis as a novel therapeutic target for cardiovascular disease Theranostics 2021 11 7 3052 9 10.7150/thno.54113 33537073
Wu X, Li Y, Zhang S, Zhou X. Ferroptosis as a novel therapeutic target for cardiovascular disease. Theranostics. 2021;11(7):3052–9. 10.7150/thno.54113.33537073
144. Latunde-Dada GO, Ferroptosis. Role of lipid peroxidation, iron and ferritinophagy. Biochimica et biophysica acta General subjects. 2017;1861(8):1893–900. 10.1016/j.bbagen.2017.05.019
145. -Xie Y Hou W Song X Yu Y Huang J Sun X Kang R Tang D Ferroptosis: process and function Cell Death Differ 2016 23 3 369 79 10.1038/cdd.2015.158 26794443
Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R, Tang D. Ferroptosis: process and function. Cell Death Differ. 2016;23(3):369–79. 10.1038/cdd.2015.158.26794443
146. -Koppula P Zhuang L Gan B Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy Protein Cell 2021 12 8 599 620 10.1007/s13238-020-00789-5 33000412
Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12(8):599–620. 10.1007/s13238-020-00789-5.33000412
147. -Wang W Green M Choi JE Gijón M Kennedy PD Johnson JK Liao P Lang X Kryczek I Sell A Xia H Zhou J Li G Li J Li W Wei S Vatan L Zhang H Szeliga W Gu W Liu R Lawrence TS Lamb C Tanno Y Cieslik M Stone E Georgiou G Chan TA Chinnaiyan A Zou W CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy Nature 2019 569 7755 270 4 10.1038/s41586-019-1170-y 31043744
Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, Xia H, Zhou J, Li G, Li J, Li W, Wei S, Vatan L, Zhang H, Szeliga W, Gu W, Liu R, Lawrence TS, Lamb C, Tanno Y, Cieslik M, Stone E, Georgiou G, Chan TA, Chinnaiyan A, Zou W. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270–4. 10.1038/s41586-019-1170-y.31043744
148. Tang J Long G Hu K Xiao D Liu S Xiao L Zhou L Tao Y Targeting USP8 inhibits O-GlcNAcylation of SLC7A11 to promote Ferroptosis of Hepatocellular Carcinoma via stabilization of OGT Adv Sci (Weinheim Baden-Wurttemberg Germany) 2023 10 33 e2302953 10.1002/advs.202302953
Tang J, Long G, Hu K, Xiao D, Liu S, Xiao L, Zhou L, Tao Y. Targeting USP8 inhibits O-GlcNAcylation of SLC7A11 to promote Ferroptosis of Hepatocellular Carcinoma via stabilization of OGT. Adv Sci (Weinheim Baden-Wurttemberg Germany). 2023;10(33):e2302953. 10.1002/advs.202302953.
149. -Schödel J Grampp S Maher ER Moch H Ratcliffe PJ Russo P Mole DR Hypoxia Hypoxia-inducible transcription factors, and Renal Cancer Eur Urol 2016 69 4 646 57 10.1016/j.eururo.2015.08.007 26298207
Schödel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P, Mole DR, Hypoxia. Hypoxia-inducible transcription factors, and Renal Cancer. Eur Urol. 2016;69(4):646–57. 10.1016/j.eururo.2015.08.007.26298207
150. -Yang Z Wei X Ji C Ren X Su W Wang Y Zhou J Zhao Z Zhou P Zhao K Yao B Song N Qin C OGT/HIF-2α axis promotes the progression of clear cell renal cell carcinoma and regulates its sensitivity to ferroptosis iScience 2023 26 11 108148 10.1016/j.isci.2023.108148 37915611
Yang Z, Wei X, Ji C, Ren X, Su W, Wang Y, Zhou J, Zhao Z, Zhou P, Zhao K, Yao B, Song N, Qin C. OGT/HIF-2α axis promotes the progression of clear cell renal cell carcinoma and regulates its sensitivity to ferroptosis. iScience. 2023;26(11):108148. 10.1016/j.isci.2023.108148.37915611
151. -Glick D Barth S Macleod KF Autophagy: cellular and molecular mechanisms J Pathol 2010 221 1 3 12 10.1002/path.2697 20225336
Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol. 2010;221(1):3–12. 10.1002/path.2697.20225336
152. -Liu S Yao S Yang H Liu S Wang Y Autophagy Regulator of cell death Cell Death Dis 2023 14 10 648 10.1038/s41419-023-06154-8 37794028
Liu S, Yao S, Yang H, Liu S, Wang Y, Autophagy. Regulator of cell death. Cell Death Dis. 2023;14(10):648. 10.1038/s41419-023-06154-8.37794028
153. Ganzleben I, Neurath MF, Becker C. Autophagy in Cancer Therapy-Molecular mechanisms and current clinical advances. Cancers. 2021;13(21). 10.3390/cancers13215575.
154. -Jin L Yuan F Dai G Yao Q Xiang H Wang L Xue B Shan Y Liu X Blockage of O-linked GlcNAcylation induces AMPK-dependent autophagy in bladder cancer cells Cell Mol Biol Lett 2020 25 17 10.1186/s11658-020-00208-x 32174982
Jin L, Yuan F, Dai G, Yao Q, Xiang H, Wang L, Xue B, Shan Y, Liu X. Blockage of O-linked GlcNAcylation induces AMPK-dependent autophagy in bladder cancer cells. Cell Mol Biol Lett. 2020;25:17. 10.1186/s11658-020-00208-x.32174982
155. Kostecki KL, Iida M, Crossman BE, Salgia R, Harari PM, Bruce JY, Wheeler DL. Immune escape strategies in Head and Neck Cancer: evade, resist, inhibit, Recruit. Cancers. 2024;16(2). 10.3390/cancers16020312.
156. -Bates JP Derakhshandeh R Jones L Webb TJ Mechanisms of immune evasion in breast cancer BMC Cancer 2018 18 1 556 10.1186/s12885-018-4441-3 29751789
Bates JP, Derakhshandeh R, Jones L, Webb TJ. Mechanisms of immune evasion in breast cancer. BMC Cancer. 2018;18(1):556. 10.1186/s12885-018-4441-3.29751789
157. -Cha JH Chan LC Li CW Hsu JL Hung MC Mechanisms Controlling PD-L1 expression in Cancer Mol Cell 2019 76 3 359 70 10.1016/j.molcel.2019.09.030 31668929
Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms Controlling PD-L1 expression in Cancer. Mol Cell. 2019;76(3):359–70. 10.1016/j.molcel.2019.09.030.31668929
158. -Gaikwad S Agrawal MY Kaushik I Ramachandran S Srivastava SK Immune checkpoint proteins: signaling mechanisms and molecular interactions in cancer immunotherapy Sem Cancer Biol 2022 86 Pt 3 137 50 10.1016/j.semcancer.2022.03.014
Gaikwad S, Agrawal MY, Kaushik I, Ramachandran S, Srivastava SK. Immune checkpoint proteins: signaling mechanisms and molecular interactions in cancer immunotherapy. Sem Cancer Biol. 2022;86(Pt 3):137–50. 10.1016/j.semcancer.2022.03.014.
159. -Zhu Q Wang H Chai S Xu L Lin B Yi W Wu L O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation Proc Natl Acad Sci USA 2023 120 13 e2216796120 10.1073/pnas.2216796120 36943877
Zhu Q, Wang H, Chai S, Xu L, Lin B, Yi W, Wu L. O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation. Proc Natl Acad Sci USA. 2023;120(13):e2216796120. 10.1073/pnas.2216796120.36943877
160. -Yuan Y Wang L Ge D Tan L Cao B Fan H Xue L Exosomal O-GlcNAc transferase from esophageal carcinoma stem cell promotes cancer immunosuppression through up-regulation of PD-1 in CD8(+) T cells Cancer Lett 2021 500 98 106 10.1016/j.canlet.2020.12.012 33307156
Yuan Y, Wang L, Ge D, Tan L, Cao B, Fan H, Xue L. Exosomal O-GlcNAc transferase from esophageal carcinoma stem cell promotes cancer immunosuppression through up-regulation of PD-1 in CD8(+) T cells. Cancer Lett. 2021;500:98–106. 10.1016/j.canlet.2020.12.012.33307156
161. -Ali A Kim MJ Kim MY Lee HJ Roh GS Kim HJ Cho GJ Choi WS Quercetin induces cell death in cervical cancer by reducing O-GlcNAcylation of adenosine monophosphate-activated protein kinase Anat cell Biology 2018 51 4 274 83 10.5115/acb.2018.51.4.274
Ali A, Kim MJ, Kim MY, Lee HJ, Roh GS, Kim HJ, Cho GJ, Choi WS. Quercetin induces cell death in cervical cancer by reducing O-GlcNAcylation of adenosine monophosphate-activated protein kinase. Anat cell Biology. 2018;51(4):274–83. 10.5115/acb.2018.51.4.274.
162. -Zhang C Niu Y Wang Z Xu X Li Y Ma L Wang J Yu Y Corosolic acid inhibits cancer progression by decreasing the level of CDK19-mediated O-GlcNAcylation in liver cancer cells Cell Death Dis 2021 12 10 889 10.1038/s41419-021-04164-y 34588426
Zhang C, Niu Y, Wang Z, Xu X, Li Y, Ma L, Wang J, Yu Y. Corosolic acid inhibits cancer progression by decreasing the level of CDK19-mediated O-GlcNAcylation in liver cancer cells. Cell Death Dis. 2021;12(10):889. 10.1038/s41419-021-04164-y.34588426
163. -Ortiz-Meoz RF Jiang J Lazarus MB Orman M Janetzko J Fan C Duveau DY Tan ZW Thomas CJ Walker S A small molecule that inhibits OGT activity in cells ACS Chem Biol 2015 10 6 1392 7 10.1021/acschembio.5b00004 25751766
Ortiz-Meoz RF, Jiang J, Lazarus MB, Orman M, Janetzko J, Fan C, Duveau DY, Tan ZW, Thomas CJ, Walker S. A small molecule that inhibits OGT activity in cells. ACS Chem Biol. 2015;10(6):1392–7. 10.1021/acschembio.5b00004.25751766
164. Loi EM, Weiss M, Pajk S, Gobec M, Tomašič T, Pieters RJ, Anderluh M. Intracellular hydrolysis of small-molecule O-Linked N-Acetylglucosamine transferase inhibitors differs among cells and is not required for its inhibition. Molecules. 2020;25(15). 10.3390/molecules25153381.
165. Li M, Duan F, Pan Z, Liu X, Lu W, Liang C, Fang Z, Peng P, Jia D. Astragalus Polysaccharide promotes Doxorubicin-Induced apoptosis by reducing O-GlcNAcylation in Hepatocellular Carcinoma. Cells. 2023;12(6). 10.3390/cells12060866.
166. -Yang R Wang L Wu Z Yin Y Jiang SW How nanotechniques could vitalize the O-GlcNAcylation-Targeting Approach for Cancer Therapy Int J Nanomed 2022 17 1829 41 10.2147/ijn.S360488
Yang R, Wang L, Wu Z, Yin Y, Jiang SW. How nanotechniques could vitalize the O-GlcNAcylation-Targeting Approach for Cancer Therapy. Int J Nanomed. 2022;17:1829–41. 10.2147/ijn.S360488.
